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Abstract 
 
The aim of this thesis is to improve our understanding of muscarinic and 
purinergic neurotransmission within the urinary bladder both within the 
detrusor muscle and the urothelium as both sites are therapeutic targets. 
 
The M2 receptor is the most populous muscarinic receptor in the detrusor 
muscle however its role is unclear, as detrusor contractility has been 
demonstrated to be mediated principally by the M3 receptor. The role of the 
M2 muscarinic receptor in guinea pig and human detrusor contractility was 
examined through organ bath experiments. Significant M2 modulation of 
contractility in patients with neuropathic overactivity and overactive bladder 
symptoms was demonstrated through inhibition of agonist dose response 
curves and electrical field stimulation with the selective M2 inhibitor 
methoctramine. Furthermore cAMP elevation through the adenylate cyclase 
activator forskolin produced an identical and non-additive inhibition to that 
achieved through methoctramine suggesting that cAMP inhibition is an 
important mechanism of M2 activation in the detrusor. 
 
Detrusor contractility was further assessed through an isolated cell technique 
and this demonstrated further evidence of M2 mediated contraction of the 
detrusor indicating that the site of action of M2 agonism is directly within the 
detrusor cells.  
 
Ussing chamber experiments to examine the effect of the exogenous addition 
of neurotransmitters on the electrical properties of the urothelium were carried 
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out. These demonstrated that cholinergic agonists had no effect but ATP 
resulted in an increased negativity of the basolateral surface of the urothelium 
only when added to the luminal but not the basolateral surface. As ATP 
release from the urothelium has been found to be associated with 
inflammation and the sensory nerves are adjacent to the basolateral surface, 
we believe this represents a sensory mechanism whereby a luminal 
inflammatory signal is transduced electrically across the urothelium to activate 
the sensory nerves. 
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Chapter 1 
 
Introduction 
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1.1 Urinary Bladder Physiology 
 
Anatomy 
The bladder is a pelvic organ, which serves to store urine produced by the 
kidneys until it is convenient for it to be expelled.  It is a hollow bodied organ, 
that’s fills with urine, which enters the bladder via the ureters (Fig 1a). The 
roof of the bladder is termed the dome and the base of the bladder the 
trigone, which extends from the two ureters to the urethra. The urethra 
remains contracted during the storage phase through the tonic contraction of 
the internal and external urethral sphincter preventing any expulsion of urine 
from the bladder into the urethra. Anatomically the bladder walls has a 
number of distinct layers, from inside to out (Fig 1b):  
1)      Urothelium, which consist of layers of transitional epithelial cells. 
2)      Suburothelium, which is in close proximity to afferent nerves. 
3)     The detrusor smooth muscle, which is innervated by efferent nerves of   
the autonomic nervous system. It consists of 3 layers; an inner and outer 
longitudinal layer and in the middle a circular layer (Wakabayashi et al. 1994). 
4) The serosal layer which is the outer lining, which is in contact with the 
peritoneum superiorly. 
Filling is not passive but a process of active relaxation of the detrusor smooth 
muscle. The high degree of compliance allows for increase in urine volume to 
near maximal levels with no increase in vesical pressure (Harris et al. 1996).  
 
Neurological Control 
The bladder and urethral sphincter are innervated by a combination of  
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Fig 1a Anatomy of the bladder 
 
 
 
Fig 1b The lining of the bladder 
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Fig 1c Neurological control of voiding. PMC –pontine micturition centre, SMC 
–sacral micturition centre 
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somatic, sympathetic and parasympathetic nerves. Control of voiding function 
involves the full length of the spinal cord, the brainstem and higher centres. 
This complexity accounts for the diversity of disease patterns seen in brain 
and spinal cord injuries. The bladder receives parasympathetic innervation via 
the pelvic nerve, which receives nerve fibres from the S2-S4 spinal roots (Fig 
1c) . The principal neurotransmitter that initiates muscle contraction is 
acetylcholine. The bladder is also innervated by the sympathetic nervous 
system via the hypogastric nerve, which receives fibres from the T10-L2 
region of the spinal column. It opposes the actions by promoting storage and 
contributes to the relaxation of the bladder during the storage phase. The 
internal urethral sphincter receives inhibitory stimulation via the sympathetic 
nervous fibres and stimulatory fibres of the parasympathetic nervous system 
carried via the pudendal nerve. The external urethral sphincter has part 
somatic innervation via the pudendal nerve. Much of bladder function is locally 
controlled at the spinal cord by two spinal reflexes. The sacral micturition  
centre (S2-S4 of the spinal column) controls receptive bladder relaxation, as 
the bladder is filling and reflex bladder contraction, which is triggered when 
the bladder has been sufficiently filled for vesical pressure to start to increase. 
Onuf nucleus (S2-S4) contributes to the guarding reflex, which is a continence 
mechanism that insures that urethral sphincter tone is increased when 
abdominal pressure increases so that stress incontinence does not occur. The 
combination of these two mechanisms in isolation produces a reflex bladder, 
which fills until the pressure starts to rise and voiding commences 
immediately. Onufs nucleus and the sacral micturition centre are under control 
of the Pontine micturition centre unless spinal cord injury has occurred. This 
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coordinates bladder contraction with urethral sphincter relaxation and assists 
in maintaining sustained bladder contractions during voiding (de Groat 2006). 
The pontine micturition centre is influenced by information from higher centres 
within the brain. These connections do no fully function until after 1-2 years of 
age and when active allow for the deferment of voiding until it is socially 
convenient to do so. 
 
Neurotransmitters at the smooth muscle neuromuscular 
junction (Motor function) 
At the neuromuscular junction a number of neurotransmitters are released 
from vesicles, in response to electrical excitation of the nerve axon. These 
neurotransmitters mediate contractility of the detrusor muscle. The principal 
neurotransmitter released is acetylcholine (Bayliss et al. 1999), which acts on 
transmembrane muscarinic receptors located on the detrusor cells. MRNA for 
all five muscarinic receptor subtypes has been detected in the human 
detrusor, however the M2 and M3 receptor subtypes are predominantly 
expressed (Mansfield et al. 2005;Wang, Luthin, & Ruggieri 1995). 
M2 receptor numbers within the detrusor, exceed that of the M3 receptor 
across a range of mammalian species, including humans where they exceed 
M3 numbers by a ratio of 3:1 (Mansfield et al. 2005;Wang, Luthin, & Ruggieri 
1995). However, the findings from animal knockout models and the use of 
selective muscarinic agonists points to contractility largely being mediated by 
the M3 receptor (Mansfield et al. 2005).The M2 receptor is believed to have a 
regulatory role, though this has yet to be clearly established.  
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M3 receptor activation has been demonstrated to activate the Gq/11 G protein. 
This was demonstrated through the inhibition of acetylcholine mediated 
contractions with specific Gq/11 antibodies (An et al. 2002). Activated Gq/11 
activates phospholipase C that leads to the production of IP3 and 
diacylglycerol. IP3 activates the IP3 receptor on the sarcoplasmic reticulum, 
which controls the release of Ca2+ from the sarcoplasmic reticulum (An, Yun, 
Lee, Yang, Shim, Jeong, Shin, Kim, Kim, & Sohn 2002). A rise in intracellular 
Ca2+ leads to a contraction by binding to calmodulin, which in turn activates 
myosin light chain kinase (MLCK). MLCK phosphorylates myosin filaments, 
and this allows crossbridge formation with actin and therefore shortening and 
the generation of force. However, the work of Schneider in human detrusor 
muscle points to an alternative mechanism for M3 activity as the 
phospoholipase inhibitor U73122 did not significantly inhibit detrusor 
contractility, whereas nifedipine the Ca2+ channel blocker and the rho kinase 
inhibitor Y27632 did so (Schneider et al 2004).  
M2 receptor activation leads to the activation of Gi/0 G protein. Activation of 
which leads to inhibition of adenylyl cyclase, which results in a reduction in 
cAMP concentration. A reduced cAMP level may potentiate detrusor 
contraction by a reduction in protein kinase A activity or increased rho-kinase 
activity (Somlyo & Somlyo 2000), both of which may result in reduced 
phosphorylation of myosin light chain phosphatase and reduced 
dephosphorylation of myosin, which constitute a calcium independent 
mechanism of potentiating the force of contractions. 
Atropine resistance of electrically mediated detrusor contraction has led to the 
search for alternative neurotransmitters. ATP has been demonstrated to 
 16
mediate detrusor contractions. ATP potentially mediates its effect through 
P2X receptors, which function as a cation channel and may promote 
extracellular Ca2+ entry; either directly through the channel or indirectly 
through depolarisation of the cell membrane and activation of voltage gated 
Ca2+ channels. ATP may also mediate contraction through activation of G 
protein coupled P2Y receptors. In the normal human detrusor the most 
commonly expressed receptor at the mRNA level is the P2X1 receptor 
(O'Reilly et al. 2001). This also appears to be the case in outflow obstruction 
(O'Reilly et al. 2002), however in idiopathic detrusor overactivity P2X2 
receptor expression is increased (O'Reilly, Kosaka, Knight, Chang, Ford, 
Rymer, Popert, Burnstock, & McMahon 2002).  
 
 
 
Intracellular Calcium and detrusor contraction. 
A rise in intracellular concentration is the key event mediating detrusor 
contraction (Wu, Kentish, & Fry 1995), however there is much debate 
regarding the relative contribution of extracellular and intracellular sources. 
Acetylcholine may facilitate a rise in intracellular Ca2+ concentrations through 
IP3 activating the IP3 receptor, which allows the egress of Ca2+ from the 
sarcoplasmic reticulum, and this is the principal mechanism mooted. 
However, the action of calcium channel blockers indicates that extracellular 
sources of Ca2+ are essential for contractility. Whether this is through 
maintenance of intracellular store levels or direct increment of intracellular 
Ca2+ concentrations prior to a contraction is a matter of contention. There are 
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several types of Ca2+ channels that may facilitate extracellular Ca2+ entry. 
Longer acting or L type voltage gated channels have been demonstrated to 
have a critical role in human detrusor contractility through the use of selective 
L type inhibitors such as nifedipine (Badawi et al. 2006). The role of the 
shorter T- type channel is controversial, with some authors finding the T-type 
inhibitor mibefradil to have little effect on human detrusor contractility while 
others have demonstrated the presence of functional T-type channels (Sui et 
al. 2007). However, Ca2+ homeostasis is complex and interdependent. There 
is evidence that extracellular Ca2+ entry may promote a major Ca2+ efflux from 
intracellular stores (Imaizumi et al. 1998).  Likewise there is evidence that 
Ca2+ efflux from intracellular stores has influence on Ca2+ influx. Jiang  (Jiang 
et al. 2005) demonstrated that the ryanodine receptor serves to decrease 
spontaneous contractions and concluded that the release of Ca2+ from 
intracellular stores could activate Ca2+ dependent K+ channels (Appendix 
Figure 5), which through their hyperpolarising effect on membrane potential 
may inhibit voltage gated Ca2+ channels. This may be compatible with the 
observation that muscarinic agonists have an inhibitory effect on L-type Ca2+ 
channels. Conversely Ca2+ efflux from intracellular stores may promote 
intracellular Ca2+ entry through the activation of store operated channels 
(Putney, Jr. & McKay 1999) though this mechanism has yet to be clarified. 
Kubota (Kubota et al. 2003) demonstrated that mitochondria play a role in 
buffering intracellular Ca2+ concentrations in the guinea pig detrusor as the 
addition of mitochondrial protonophore resulted in depolarisation of the 
detrusor membrane and a rise in intracellular Ca2+ concentration. 
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Urothelial Function 
The urothelium is the epithelial lining of the bladder that is in contact with the 
urine. It is typically consist of 3 to 7 layers of cells. There are three types of 
cells; an outermost layer of large flattened hexagonal cells (termed umbrella 
cells) an intermediate layer of cells and a basal layer of cells which have a 
lower turnover rate of 3-6 months and are believed to differentiate into the 
other cell types (de Groat 2004). The urothelium serves as a barrier between 
the urine and the interstitial space as urine is a noxious substance. The 
umbrella cells in particular are believed to be important in this respect as they 
have tight gap junctions between them and are coated on their surface by a 
protein called uroplakin which reduces the permeability of the urothelium to 
small molecules such as water, urea and protons (Apodaca 2004). It has been 
demonstrated that this barrier function is compromised in a number of 
pathological conditions such as spinal cord injury (Apodaca et al. 2003) and 
interstitial cystitis (Truschel et al. 2002) and has been postulated that the 
passage of these substances through the urothelium can precipitate urinary 
symptoms such as urgency and incontinence.  
There is growing interest in the role that the urothelium may play in relaying 
bladder sensation. The urothelium has some neuronal characteristics, 
demonstrated by the expression of numerous receptor subtypes including, 
muscarinic, purinergic, nicotinic and transient receptor potential receptor 
channels, amiloride sensitive and mechanosensitive Na+ channels. The 
urothelium has been demonstrated to release a number of neurotransmitters 
in response to bladder stretch and inflammation; ATP (Truschel et al. 2002), 
acetylcholine (Yoshida et al. 2004), nitrous oxide (de Groat 2004) and 
 19
substance P. The basal surface of the urothelium is in close contact with 
sensory nerves and these substances may potentially modulate afferent 
nerves directly or via interstitial cells, which lie in close proximity. Likewise it is 
likely that substances released from the axons of sensory nerves modulate 
urothelial function. Neurotransmitters released from the urothelium may have 
a direct effect on detrusor contractility. It has been postulated that detrusor 
overactivity may be due to these substances being excessively released form 
the urothelium during the storage phase when the efferent parasympathetic 
nerve fibres are quiescent.  
The direct effect of the urothelium on the detrusor has been investigated 
through the comparison of detrusor contractility when the urothelium is 
present and removed, both in human (Chaiyaprasithi et al. 2003) and guinea 
pig tissue (Hawthorn et al. 2000). In both cases, detrusor contractility was 
increased when the muscle strips were denuded of the urothelium. The 
authors concluded that some diffusible substance released from the 
urothelium was responsible for inhibiting detrusor contractions, however this 
substance remains unidentified as the authors concluded that it was not 
nitrous oxide or a catecholamine due to the lack of activity of ODQ and L-NG –
nitroarginine (inhibitors of nitrous oxide synthesis) or propanolol (B-blocker) 
respectively (Chaiyaprasithi, Mang, Kilbinger, & Hohenfellner 2003). 
Furthermore, the diffusible substance does not seem to be ATP or to mediate 
its actions through K+ channels (which when activated may hyperpolarize a 
cell membrane and inhibit contractility), as the purinergic inhibitor suramin and 
the K+ channel inhibitors apamin, TEA had no effect in inhibiting detrusor 
contractions (Hawthorn, Chapple, Cock, & Chess-Williams 2000). 
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ATP has been shown to be independently released from both the basal and 
apical surface of the urothelium (Lewis & Lewis 2006). The purpose of apical 
release is unknown given the basal location of the sensory nerves but this 
may serve some regulatory function. ATP release has been demonstrated to 
be increased in a number of inflammatory conditions, including UTI 
(Osterberg et al. 1991) and interstitial cystitis (Sun & Chai 2002). The 
expression of urothelial P2X2 and P2X3 receptors has been found to be 
increased in patients with interstitial cystitis and inflammation of the bladder. 
Interstitial cystitis in cats has been shown to lead to the increased excitability 
of sensory neurons within the dorsal root ganglion (Sculptoreanu et al. 2005). 
Furthermore experiments with P2X3 deficient mice have shown them to have 
impaired voiding function (Cockayne et al. 2000). There is good evidence that 
purinergic signalling is an important component of urothelial sensory function. 
Acetylcholine has likewise been demonstrated to be released from the 
urothelium in a stretch dependent fashion. Yoshida found that muscle strips 
released more acetylcholine when the urothelium was present when 
compared to denuded detrusor muscle strips. This release was demonstrated 
to be non neuronal as it was uninhibited by the addition of tetrodotoxin which 
abolishes nerve activity (Yoshida, Miyamae, Iwashita, Otani, & Inadome 
2004). The authors concluded that this might be part of a bladder sensory 
mechanism. 
 
Temperature-sensitive transient receptor potential vanilloid (TRPV) ion 
channels
 are believed to play a role in mediating bladder sensation (Birder et 
al. 2002). They are expressed within the urothelium and within c fibre sensory 
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nerves mediating bladder sensation. These receptors may depolarise the 
membrane through the opening of a cation channel and are believed to be 
important in nociception and perhaps serve as “environmental sensors”. 
There are a number of subtypes expressed within the bladder. The TRPv1 
receptor is activated by irritant stimuli such as capsaicin, which is a 
component of chilli peppers and anandamide, which is an exogenous ligand 
for the valinoid and canabinoid receptor. It is also activated by heat and 
changes in pH and osmolality. Activation of urothelial TRPV1 receptors has 
been demonstrated to lead to a rise in intracellular Ca2+ and enhanced 
release of the neurotransmitters ATP and Nitrous Oxide. Cultured urothelial 
cells from TRPV1 null mice show a decrease in hypotonic solution induced 
ATP release (Birder et al. 2002). 
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Disorder of bladder function 
 
Overactive Bladder Symptoms (OAB) 
Overactive Bladder symptoms as defined by the International Continence 
Society is characterised by urinary urgency; “a compelling desire to pass urine 
that is difficult to defer, ± urinary frequency (greater than 8 voids per day) ± 
nocturia (greater than one void per night),  ± urge incontinence (Chapple et al. 
2005). Overactive bladder symptoms are associated with detrusor 
overactivity, which is characterised by the presence of detrusor contractions 
during the filling phase on urodynamic assessment (Hashim & Abrams 2006). 
However detrusor overactivity and overactive bladder symptoms as they are 
strictly defined may exist in patients independently of each other. 
 OAB is a common condition that affects a large proportion of the elderly 
population but has a significant incidence amongst younger individuals. The 
prevalence of OAB has been estimated as 11%  (Irwin et al. 2006; Milsom et 
al. 2001) and 16% (Tubaro 2004). OAB is a large social problem; a recent 
estimate has put the cost of OAB to the UK economy at £743 per year 
(Hashim & Abrams 2004). It was estimated that OAB cost five EEC countries 
in excess of €4.2 billion in the year 2000 (Reeves et al. 2006). OAB is 
independently associated with falls and fractures, urinary tract and skin 
infections, sleep disturbances and depression (McGrother et al. 2006; Ragins 
et al. 2008).  The clinical impact of this syndrome is likely to increase greatly 
as the world’s population ages (Irwin et al. 2006). 
The pathophysiology of OAB is unknown though a number of theories have 
been proffered. Occult infection manifest by pyruria on fresh unspun urine has 
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been suggested as a common cause of OAB with up to 70% of patients with 
OAB having pyuria, yet by conventional urinary testing most of these patients 
would be deemed free of infection (Malone-Lee 2007). It has been 
demonstrated that UTI with uropathic escherichia coli is initiated by adherence 
of the bacteria to the outer uroplakin layer of the umbrella cells and formation 
of intracellular colonies termed biopods (Schilling & Hultgren 2002) and it is 
possible than such colonies exist in patients with OAB giving rise to chronic 
low grade infections that may be difficult to diagnose or treat with current 
therapeutic protocols. 
 
Neuropathic disorders 
Neuropathic disorders can present both with symptoms of overactivity or 
hyperreflexia. If the neurological lesion is superior to the sacral micturition 
centre and there is loss of descending inhibition from the pontine micturition 
centre then hyperreflexia may arise. If the motor neurones in the sacral 
micturition centre are damaged then the bladder will become areflexic. There 
is evidence of alteration in muscarinic function in patients with neuropathic 
bladders. Pontari (Pontari, Braverman, & Ruggieri, Sr. 2004) inferred 
increased M2 muscarinic receptor signalling in four out of seven neuropathic 
patients. Braverman (Braverman et al. 1998) found evidence of increased M2 
muscarinic signalling in rats, which had spinal cord transection relative to 
control animals. 
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Painful Bladder Syndrome 
Painful bladder syndrome is difficult to treat and to characterise pathologically 
but is defined by the International Continence Society as the complaint of 
suprapubic pain related to bladder filling, accompanied by other symptoms 
such as increased daytime and night time frequency, in the absence of proven 
urinary infection or other obvious pathology.  The condition has been treated 
by bladder hydrodistension and various pharmacological agents. A recent 
review (Dimitrakov et al. 2007) found little evidence of patient benefit for any 
treatment other than pentosan polysulphate. 
 
Bladder outflow obstruction 
Bladder outflow obstruction is much more common in men than women who 
have a longer urethra and the potential for prostatic obstruction. Bladder 
outflow obstruction may be caused by benign prostatic hypertrophy, prostate 
cancer, bladder neck hypertrophy, and urethral strictures. Voiding symptoms 
which characterise BOO have a prevalence of 37% in males aged >60 (Irwin 
et al. 2006), and are most commonly due to benign enlargement of the 
prostate. 
Voiding symptoms; poor stream, hesitancy, post micturition dribbling and 
incomplete emptying are associated with bladder outflow obstruction (BOO). 
Storage symptoms; urinary frequency, urgency, nocturia and incontinence are 
associated both with the overactive bladder (OAB) and BOO (Abrams et al. 
2002). In BOO, the voiding symptoms are thought to be primarily due to the 
effect of the obstruction on urinary flow whereas the storage symptoms are 
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due to the effect that the obstruction has on bladder function (Morant et al. 
2008).  
BOO is characterised by an elevated detrusor pressure relative to the urinary 
flow rate in the earlier stages of the disease process.  However chronic 
obstruction can lead to marked and irreversible changes in bladder function 
characterised by an increase in bladder capacity from the normal value of 
500-600 mls to 1 –4 litres and a decrease in voiding pressure such that 
retention of urine persists after the obstruction has been surgically treated. 
Such patients are said to have an acontractile bladder and may be dependent 
on lifelong catheterisation as untreated they are prone to infections and life 
threatening renal impairment. 
 
 
Pharmacological treatments of bladder disorder 
 
Anticholinergic Drugs 
 
Anticholinergic drugs are the most common form of treatment used for OAB. 
They act through inhibiting the function of the neurotransmitter acetylcholine. 
They primary effect is believed to be at the neuromuscular junction where 
they act to reduce contractions during the filling phase, however as much less 
is known about urothelial function, inhibition of sensory signalling and the 
influence that this has on the voiding reflex is something that cannot be 
discounted. 
The antimuscarinic drugs used today are similar in their efficacy and side 
effects profile. The principal stated targets are the M3 muscarinic receptors as 
these have previously been shown to mediate detrusor contractions, however 
all of these drugs will have activity at the other muscarinic receptor subtypes. 
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The most common side effects that patients complain of are due to M3 
inhibition; dry mouth, constipation and blurred vision. M2 inhibition can 
potentially cause tachycardia through their action on cardiac receptors and 
may affect the patient’s memory, if the molecule can traverse the blood brain 
barrier (Caulfield & Birdsall 1998). 
 
Botulinum toxin injections 
 
Botulinum toxin injections into the bladder have proved an efficacious 
treatment for patients with overactive urinary symptoms that are refractory to 
antimuscarinic drug treatment. This has been demonstrated in OAB (Ghei et 
al. 2005), neuropathic detrusor overactivity (Giannantoni et al. 2008) and 
painful bladder symptoms (Giannantoni et al. 2008).  
 
Botulinum toxin acts by cleaving the subunit of SNARE1, a type of SNAP 
protein that is essential for the formation of presynaptic neurotransmitter 
vesicles (Kalandakanond & Coffield 2001). In skeletal muscle this results in 
abolition of presynaptic vesicular release of the neurotransmitter acetylcholine 
and ATP from the neuromuscular junction. By analogy it is believed to have 
an identical effect on the human detrusor though this needs to be 
demonstrated experimentally. It is possible, given that the same 
neurotransmitters are released from the urothelium albeit by alternative 
mechanisms that botulinum toxin has an effect on afferent nerve function 
though again this hypothesis is one that needs to be tested experimentally. 
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1.2 Muscarinic Receptors 
 
Introduction 
Acetylcholine is a signalling molecule, which has extensive actions within the 
mammalian nervous system, acting both centrally and peripherally. Unusually 
for a signalling molecule, acetylcholine acts on two unrelated families of 
receptors- the nicotinic and muscarinic receptors, distinguished by their 
selective response to nicotine and muscarine respectively. In fact muscarinic 
receptors share greater sequence homology with B adrenergic and 
dopaminergic receptors than the nicotinic receptors (Hosey 1992). In the 
periphery, nicotinic receptors mediate the synaptic action of the skeletal 
neuromuscular junction, whereas muscarinic receptors mediate the action of 
the postganglionic neurons of the parasympathetic nervous system. Nicotinic 
receptors are fast acting as a result of their ionotropic effects whereas 
muscarinic receptors generally provide a slower metabotropic response. 
Muscarinc receptors have been extensively studied due to their wide range of 
physiological actions, which includes cerebral, cardiovascular, bowel and 
urinary function. Whilst the complexity of the field has rapidly increased, so 
has the potential for therapeutic interventions for the range of disease 
processes which are influenced by muscarinic receptor function. 
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Discovery of muscarinic receptor subtypes and their genes 
Five mammalian receptor subtype (M1-M5) have been discovered through the 
elucidation of the genes encoding for them (Bonner et al. 1987;Bonner et al. 
1988;Hosey 1992;Kubo et al. 1986;Peralta et al. 1987)). The M1-M5 genes are 
localised to 11q12-13, 7q35-36, 1q43-44, 11p12-11.2 and 15q26 respectively 
within the human chromosome (Bonner 1989). There is considerable 
homology in amino acid sequences between the mammalian species whose 
receptors have been cloned thus far. For example there is 97% homology 
between human and porcine M2 receptors at the amino acid level (Hulme, 
Kurtenbach, & Curtis 1991). However, variation of even a single amino acid 
can lead to greatly differing receptor pharmacology. As such transfection of 
the cloned human muscarinic receptor to a cell line should provide a superior 
model of human receptor functionality than a non human mammalian species  
(Caulfield & Birdsall 1998) (Table 1, page 29). 
The human muscarinic receptor genes have the following number of exons; 
M1 2 exons M2 3-4 exons,M3 5 exons,M4 2 exons, M5 receptor 2 exons. 
In the case of the M2 receptor gene, eight alternatively spliced gene products 
have been discovered. Variation is solely in the 5’ UTR and the same protein 
(isoform a) is always produced. Alternative transcripts have not been found to 
be products of the other muscarinic receptor genes. 
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Table 1, Muscarinic receptors gene homology.  
Number of amino acids (percentage of identity with human sequence). 
 
 
(Caulfield & Birdsall 1998)
  
  
Species 
 
  
  
M1 
 
  
  
M2 
 
  
  
M3 
 
  
  
M4 
 
  
  
M5 
 
  
Human 
 
  
460 
 
  
466 
 
  
590 
 
  
479 
 
  
532 
 
  
Pig 
 
  
460 
(99%) 
 
  
466 
(97%) 
 
  
590 
(96%) 
 
  
  
 
  
 
  
Rat 
 
  
458 
(98%) 
 
  
466 
(95%) 
 
  
589 
(92%) 
 
  
478 
(95%) 
 
  
531 
(89%) 
 
  
Chicken 
 
  
 
  
466 
(92%) 
 
  
639 
(87%) 
 
  
490 
(76%) 
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Structure 
The three dimensional structure of the muscarinic receptor has yet to be 
elucidated, however muscarinic receptors are G-protein coupled receptors 
and as such have seven transmembrane helices. G-protein coupled receptors 
are the most extensive family of plasma membrane localised receptors and 
account for > 1% of the human genome (Breitwieser 2004). It is predicted that 
its three dimensional structure will be similar to that of rhodopsin (Baldwin 
1993) . In addition muscarinic receptors have the following structural motifs: 
The transmembrane segments are most likely alpha helical. The carboxy 
terminus is on the intracellular side of the membrane. As antibodies to the 
carboxy terminus only demonstrate immunoreactivity when the cells are 
permeabilised (Lu et al. 1997).  There are two cysteine residues that form a 
disulphide bond between the first and third extracellular loops (Kurtenbach et 
al. 1990). All muscarinic receptors have an Aspartate residue in the distal N 
terminal part of the third transmembrane domain which is believed to interact 
with the polar head group of amine ligands eg acetylcholine (Caulfield & 
Birdsall 1998). The ligand-binding site is in the outer portion of the receptor. 
However, the sites involved in the binding of muscarinic receptor antagonists 
are believed to be diverse (Wess, Bonner, & Brann 1990). Muscarinic 
receptors possess a large third intracellular loop (i3), which becomes 
phosphorylated by endogenous protein kinase (Pals-Rylaarsdam & Hosey 
1997). This region along with the second intracellular loop is important for the 
interaction between the receptor and its target G proteins. In this region there 
is sequence divergence between M1/M3/M5 receptors and M2/M4 receptors, 
which determines that the former interact with q/11 G proteins and the latter 
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i/o G proteins. Studies with chimeras of the M2 and M3 muscarinic receptor 
have shown that the transfer of small amino acid segments of under 21 amino 
acids in length between these two receptors can cause an M2 receptor to 
signal like an M3 receptor and vice-versa (Wess, Bonner, & Brann 1990).  
 
 
Heterodimers/ Homodimers 
Protein dimerization and oligomerization is a ubiquitous process found in all 
living organisms and functionally important in many biological signalling 
systems, including G-protein coupled receptors (Milligan et al. 2003). It has 
been demonstrated that proteins that have the ability to self interact (dimerize) 
have a greater propensity to interact with other proteins than would be 
expected by chance (Ispolatov et al. 2005). Paralagous proteins that are 
involved in heterodimerization may have evolved by duplication of genes 
encoding proteins that are able to form homo-dimers. This property may 
confer proteins with several advantages including structural stability (Hattori et 
al. 2003), control of binding site accessibility (Marianayagam, Sunde, & 
Matthews 2004), increasing the range of structural complexity and 
phenotypes available from a genome of a particular size (Ispolatov, Yuryev, 
Mazo, & Maslov 2005).  
There is much evidence for the existence of muscarinic receptor homodimers 
and higher order homo-oligomers (Park & Wells 2004) and for 
heterodimerization between muscarinic receptor subtypes and even other 
members of the G-protein coupled receptor family. Though some of the 
inferences need to be tempered by the possibility that the methodology 
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employed to study dimerization, such as the use of mutant receptors or co-
immunoprecipitation may produce interactions that are not representative of 
those that occur between wild type receptors in vivo. These potential 
drawbacks can be overcome through the use of newer techniques such as 
bioluminescence resonance energy transfer (BRET) which studies real time 
interactions between proteins in vivo (Breitweiser 2004; Goin & Nathanson 
2006). Ligand binding studies of muscarinic receptors have indicated the 
formation of dimers as complex binding pharmacology has been observed, 
suggesting multiple states of affinity consistent with either dual binding sites 
on a dimeric protein (Hirschberg & Schimerlik 1994; Potter et al. 1991) or 
cooperative interactions between activated monomers (Chidiac et al. 1997).  
Most dimers are not connected by covalent bonds, the exception to this is 
disulphide bridge linkage, which has been demonstrated between M3 
homodimers and has been shown to involve the Cys 140 and Cys 220 
residues. Two modes of interaction between receptors have been described; 
1) contact dimerization and 2) domain ”swapping” (Breitwieser 2004).  Contact 
sites have been identified for a few GPCR homodimers such as the B-
adrenergic receptor (Hebert et al. 1996) and the D2 dopaminergic receptor 
(Guo, Shi, & Javitch 2003). Domain swapping was first suggested as a 
cooperative mechanism by Maggio and his colleagues as they demonstrated 
functional rescue of a non functional mutated M3 receptor via coexpression of 
an α2c receptor (Maggio, Vogel, & Wess 1993). The question as to whether 
muscarinic receptors exist constitutively within the plasma membrane as 
dimers or whether dimerization of a monomer is promoted by agonist-induced 
activation of a monomer has been raised. The work of Zeng (Zeng & Wess 
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1999) and Goin  (Goin & Nathanson 2006) suggests that it is the former rather 
than the latter. Relatively little is known about the functional consequences of 
dimerization. Of particular interest is the effect that muscarinic receptor 
dimerization has on the G-protein mediated interactions with the principal 
downstream effectors- phospholipase C and adenylyl cyclase. Novi 
demonstrated that activation of both components of the M3 homodimer are 
necessary for the activation of Extracellular receptor kinase 1/2, but G-protein 
activation could occur simply by activation of a single component of the 
homodimer (Novi et al. 2004). Novi later demonstrated that the formation of 
paired agonist activated wild type M2 dimers, M2/M3 heterodimers, α2 
adrenergic/ M3 muscarinic heterodimers were a prerequisite for the 
recruitment of the G-protein regulatory protein β-arrestin-1 to the plasma 
membrane (Novi et al. 2005). 
 
Localization of muscarinic receptors and physiological function in 
mammalian studies 
 
M1 receptor; Brain (Levey et al. 1991), Memory- activation of MAP kinase, 
glands (Hamilton et al. 1997), sympathetic ganglia (Ramcharan & Matthews 
1996). 
 
M2 receptor Heart (Hoover, Baisden, & Xi-Moy 1994), hindbrain (Levey et al. 
1991), smooth muscle, detrusor and urothelium (Mukerji et al. 2006). 
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M3 receptor; Smooth muscle (Caulfield & Birdsall 1998), detrusor and 
urothelium (Mukerji et al. 2006), salivary glands causing secretion, pupils – 
constriction (Matsui et al. 2000),  brain (Levey et al. 1991). 
 
M4 receptor; Basal forebrain striatum (Caulfield & Birdsall 1998), central 
dopaminergic response regulation (Gomeza et al. 1999), adrenal chromafin 
cells (Endo et al. 2005). 
 
M5 receptor; Substantia Nigra (Reever, Ferrari-DiLeo et al. 1996), 
involvement in thr reward pathways of mice (Forster et al. 2002;Yeomans, 
Forster, & Blaha 2001), iris cilliary muscle  (Ishizaka et al. 1998). 
 
Table 2 Summary of muscarinic receptor distribution, function and mechanism 
of action (Caulfield & Birdsall 1998)
 
Inhibition of 
Ca2+ 
channels 
Gland 
secretion, 
smooth 
muscle 
contraction 
Inhibit Ca2+ 
channels, 
decreased 
heart rate 
 
Functional 
response 
q/11 
PLC 
IP3/DAG 
Ca2+/PKC 
i/0 
-(AC) 
q/11 
PLC 
IP3/DAG 
Ca2+/PKC 
i/0 
-(AC) 
q/11 
PLC 
IP3/DAG 
Ca2+/PKC 
Preferred 
G protein 
secondary 
messenger 
Substantia 
nigra 
Basal 
forebrain 
Smooth 
muscle, 
Glands, 
 brain 
Heart, 
Hindbrain, 
smooth 
muscle 
Brain, 
Glands, 
Sympathetic 
ganglia 
Location 
 
M5 
 
M4 
 
M3 
 
M2 
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Mechanisms of action 
G proteins are a family of signalling molecules, which interact with surface 
membrane receptors. They are heterotrimeric proteins consisting of α,β and γ 
subunits. There is some evidence to suggest that the normal stoichometry for 
this interaction is between a muscarinic receptor dimer and a G protein trimer. 
This is derived from analogous studies of the interaction of rhodopsin with G-
proteins (Clark et al. 2001;Willardson et al. 1993). The G proteins are 
classified according to the α subunit, of which there are four main classes; αs, 
αi, αq and α12. There is also considerable variability in the β and γ subunits 
and hence multiple permutations of G-protein complexes are possible. Ligand 
binding to the G-protein coupled receptor results in a conformational change 
which allows the α subunit to catalyse the exchange of GDP for GTP. GDP 
release is the rate limiting step in the cyclical function of the α subunit 
(Ferguson et al. 1986). The α subunits dissociate from the βγ subunits which 
are each independently able to activate a range of divergent downstream 
targets. G protein deactivation occurs by the intrinsic hydrolysis of GTP to 
GDP by the α subunit. It is likely that our knowledge of these pathways and 
their regulatory factors will increase such that we may be able to understand 
how a particular pathway attains physiological prominence within a specific 
tissue type. This in turn may lead to specific pharmacological modulation of a 
pathway for therapeutic purposes. The best understood signalling pathway is 
the Gq/11 / IP3 pathway in smooth muscle but evidence for other mechanisms 
is also described below. 
The M1/M3/M5 receptors activate the α subunit of the Gq/11 protein which can 
activate Phospholipase C and Phospholipase D.  Phospholipase C activation 
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results in increased IP3 and 1,2,-diacylglycerol (DAG).  IP3 activates the IP3 
receptor, which results in the release of Ca2+ from the sarcoplasmic reticulum. 
A rise in Intracellular Ca2+ is the critical event leading to smooth muscle 
contraction. Basal intracellular Ca2+ levels are maintained at 0.01uM to 0.1uM. 
Contractile proteins are sensitive to a rise in Ca2+ in the 0.1uM to 10uM range 
(Wu, Kentish, & Fry 1995). Ca2+ binds to calmodulin leading to the formation 
of Ca2+-calmodulin complex, which is able to activate myosin light chain 
kinase (MLCK). MLCK phosphorylates myosin light chain, which triggers 
cycling of crossbridges with actin resulting in ATP hydrolysis and muscle 
contraction. Diacylglycerol activates protein kinase C, which has numerous 
downstream targets.  
The M2/M4 receptor couples to the α subunit of the Gi/0 protein which inhibits 
adenylcyclase and results in decreased cAMP concentrations. It has been 
proposed that this may counteract mechanisms, which increase cAMP 
concentrations such as β adrenergic signalling. cAMP has numerous 
downstream effectors. Reduced cAMP levels could potentially modulate 
smooth muscle contraction via activation of rho-kinase or inhibition of protein 
kinase A (Somlyo & Somlyo 2004). Both of which may lead to phosphorylation 
and deactivation of myosin light chain phosphatase and prolonged activation 
of myosin. Such a mechanism could lead to increased contractility at a given 
intracellular Ca2+ concentration (Ca2+ sensitisation) or potentially a contraction 
independent to a rise in given intracellular Ca2+ concentration.  
There are also reports of muscarinic receptors activating adenylcyclase, in a 
pertussis toxin sensitive manner, in the case of the rat olfactory bulbs (Onali & 
Olianas 1995). 
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Muscarinic receptors have been reported to have ionotropic function. In 
cardiac muscle; M2 mediated inhibition of voltage gated Ca2+ channels via 
adenylcyclase inhibition (Mery et al. 1997) and also direct activation by M2 
receptors of inward K+ rectifier current by Gβγ subunits (Wickman & Clapham 
1995). In the guinea pig ileum M2 activity stimulates the opening of cation 
selective channels, which result in depolarisation and contraction (Zholos & 
Bolton 1997). 
Muscarinic receptors are also located presynaptically and may function to 
modulate the release of acetylcholine and other neurotransmitters from 
parasympathetic nerve terminals. D’Agostino demonstrated that pre-junctional 
M4 receptors participate in a negative feedback regulatory mechanism by 
inhibiting the release of acetylcholine from parasympathetic nerve terminals 
(D'Agostino et al. 1997). 
 
 
Human genetic Polymorphism 
Polymorphisms are the differences between humans or animals of the same 
species. The genetic variation which account for our individuality, be it 
physical or psychological characteristics or disease predisposition are being 
uncovered all the time. The human genome project has greatly facilitated our 
understanding of the genetic basis of disease by providing an open database, 
which scientists throughout the world may explore. Evolutionary pressure 
insures that the genome is highly conserved. According to our current 
knowledge there is 99.7% homology of human DNA between individuals. 
Thus one in every 300 bases within the genome varies and contributes to our 
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individuality. However, this number may rise, as less frequent genetic 
polymorphisms are uncovered through probing of DNA from a wider range of 
individuals. The most common type of genetic polymorphisms are single 
nucleotide polymorphism (SNP). A single DNA base is altered and thus the 
single subtlest change in the genome occurs.  SNP will usually result in 2 
alleles i.e. variation results in only 2 out of the 4 possible bases occurring at 
that point in the genome.  Traditionally base changes are classed as SNPs if 
the minor allele arises with a frequency of greater than 1%. This is arbitrarily 
so that the changes in the genome represent variations that are conserved 
rather than those which arise out of spontaneous mutations. SNPs may occur 
in regions of DNA, which code for proteins  (exon) or regulatory regions 
(introns) or within an intergenic region. Polymorphism arising in introns may 
affect the control of genes and thus the timing and quantity of protein 
synthesised may be altered. SNPs arising in exons may cause no change to 
the protein synthesised (synchronous SNP) or may alter one of the amino 
acids (asynchronous change) and thus may alter the function of the protein 
that is synthesised.  Genetic polymorphism of the muscarinic receptor has 
been implicated in the development of asthma (Yamamoto et al. 2007), 
prolonged heart rate recovery from exercise (Hautala et al. 2006) and 
cognitive function (Gosso et al. 2006). However, in the overactive bladder, 
there are currently no such documented associations between muscarinic 
receptor polymorphism and bladder function, though an association has been 
found between seretonin 2A receptor genetic polymorphism and urinary 
incontinence in women (Noronha et al. 2010). The experience of our 
laboratory is that there can be a wide difference in agonist EC50 values (up to 
 39
30 fold) when comparing detrusor contractions from bladder biopsies from 
different individuals. A possible explanation for this is genetic polymorphism of 
the muscarinic receptor.  
 
Known polymorphic regions within human muscarinic receptor genes 
Muscarinic receptor gene polymorphism has been implicated as a 
predisposing factor in a number of phenotypes and disease processes, both 
of early and late onset. Some of these SNPs and their significance are 
described below. Much of the pre-eminence in this field has been gained by 
those studying human cognitive and behavioural function; 
 
M1 receptor gene, CHRM1;  
Two SNPs (-9697C > T and -4953A > G) were associated with asthma 
(Yamamoto, Matsubara, Maeda, Minagawa, Takashima, Maruyama, 
Michikawa, & Yanagisawa 2007). 
 Reduced M1 receptor cDNA expression in patients with schizophrenia 
(Yamamoto et al. 2007).  
 
M2 receptor gene, CHRM 2;  
An SNP at intron 5 rs32460 resulting in a sequence change from T/T to C/C 
and an SNP at rs8191992 in the 3’ – untranslated region of exon 6 resulted in 
significantly differing tachycardia post exercise (Hautala, Rankinen, Kiviniemi, 
Makikallio, Huikuri, Bouchard, & Tulppo 2006). 
Two degenerate SNPS (1197T→C and 976A→ C were found not to be 
significantly associated with the asthma phenotype. 
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Association was between rs324650 and performance IQ (PIQ), where the T 
allele was associated with an increase of 4.6 PIQ points (Gosso, van, de 
Geus, Polderman, Heutink, Boomsma, & Posthuma 2006). 
Three SNPs (one in intron 4 rs184240 and two in intron 5 rs324640, 
rs324650) showed significant association with alcoholism. Two SNPs (both in 
intron 4 rs184240 and rs2061174) were significantly associated with major 
depressive syndrome (Wang et al. 2004).  
Chrm2 variability associated with agreeableness and conscientiousness (Niu, 
Luo, & Hao 2004). 
 
M3 receptor gene, CHRM 3;   
Gene variation is associated with decreased acute insulin secretion and 
increased risk for early-onset type 2 diabetes in Pima Indians (Guo et al. 
2006). 
No association between coding region of M3 receptors and the asthma 
phenotype (Donfack et al. 2003). 
 
M4 receptor gene, CHRM 4;  
No published studies 
 
M5 receptor gene, CHRM 5;   
A 26.8% increase in cigarette consumption in carriers of the rs7162140 T-
allele. Carriers of the rs7162140 T-allele were also found to have nearly a 3-
fold increased risk of developing cannabis dependence (Anney et al. 2007). 
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Muscarinic Agonists 
Acetylcholine, the physiological agonist contains a quaternary nitrogen, which 
allows interaction with the anionic receptor site. This is illustrated by the fact 
that dimethylaminoethylacetate which is the tertiary form of acetylcholine, has 
an approximately 1000 fold reduced affinity for the receptor. Other agonist, 
such as muscarine and carbachol, share this structural feature. However, 
other agonists of high potency- oxotremorine and pilocarpine contain tertiary 
amines. Experimentally carbachol and oxotremorine have been the most 
utilized in functional studies. There are no highly selective agonists, though 
oxotremorine has some selectivity for the M2 receptor over the M3 receptor 
(Pkb =7.1 and 6.0 respectively) (Griffin et al. 2003). Carbachol and 
oxotremorine have the ability to activate phospholipase A2 and inhibit 
adenylylcyclase, albeit at different concentrations. Carbachol has been 
demonstrated to preferentially activate phospholipase A2 at lower 
concentrations whilst oxotremorine preferentially inhibits adenylylcyclase at 
lower concentrations (Griffin et al. 2003). Muscarinic agonist potency and 
hence selectivity, is greatly determined by the tissue or cell line under study 
and findings from a given functional study may not be generalisable. The 
search for functionally selective agonists have deemed to be a potential 
avenue for treatment of Alzheimer’s disease (Fisher 2008), however there are 
currently no treatments that have demonstrated efficacy.  
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Muscarinic Antagonists 
Atropine is an alkaloid originally derived from the nightshade plant- Atropa 
Belladonna and one of the oldest known molecules. It possesses an N-methyl 
group. It has a much higher pKB than any other known antagonists and has no 
selectivity between muscarinic receptor subtypes. There are currently no 
antagonists, which are highly specific for a particular muscarinic receptor 
subtype, with the exception of MT7 muscarinic receptor snake venom, which 
is highly selective for the M1 receptor (Bradley, Rowan, & Harvey 2003). To 
illustrate this problem; in attempting to distinguish between the M2 and M3 
receptors which are highly expressed throughout the nervous system, no 
antagonist has a greater than 30 fold preference between these two subtypes.  
Gallamine is an allosteric inhibitor with preference for the M2 receptor over the 
M3 inhibitor. However its mechanism of action may produce complex 
interactions with other ligands. It has been demonstrated that gallamine can 
act as an agonist in the absence of orthosteric agonists and that this function 
is not inhibited by classical antagonists (Jakubik et al. 1996). 
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Table 3 Muscarinic antagonists and their receptor specific pKB. 
 
Muscarinic receptor 
 
Antagonist 
 
M1 
 
M2 
 
M3 
 
M4 
 
M5 
 
Atropine 
 
 
9.0-9.7 
 
9.0-9.3 
 
8.9-9.8 
 
9.1-9.6 
 
8.9-9.7 
 
Methoctramine 
 
 
71-7.8 
 
7.8-8.3 
 
6.3-6.9 
 
7.4-8.1 
 
6.9-7.2 
 
4-DAMP 
 
 
8.6-9.2 
 
7.8-8.4 
 
8.9-9.3 
 
8.4-9.4 
 
8.9-9.0 
 
Pirenzapine 
 
 
7.8-8.5 
 
6.3-6.7 
 
6.7-7.1 
 
7.1-8.1 
 
6.2-7.1 
 
Darifenacin 
 
 
7.5-7.8 
 
7.0-7.4 
 
8.4-8.9 
 
7.7-8.0 
 
8.0-8.1 
 
MT7 
 
 
9.8 
 
<6 
 
<6 
 
<6 
 
<6 
 
Gallamine 
 
  
6.2 
 
4.5 
  
 
Oxybutynin 
 
 
8.5 
 
7.8 
 
8.7 
 
8.2 
 
7.6 
 
Tolteridine 
 
 
8.5 
 
9.4 
 
8.5 
 
8.1 
 
8.6 
 
(Caulfield 1993), (Hou, Hirshman, & Emala 1998), (Eglen & Watson 1996) 
 
 
Constitutive receptor activity. 
It has been demonstrated that muscarinic receptors can activate G-proteins in 
the absence of any agonist. In a patch clamp study of atrial cells, muscarinic 
antagonists were able to elevate cAMP levels (Soejima & Noma 1984). 
Constitutive activity has also been demonstrated in studies where there was 
over expression of the receptor or G-proteins (Burstein, Spalding, & Brann 
1997;Vogel et al. 1995). Furthermore, mutant muscarinic receptors with 
constitutive activity have been created in the case of M1 (Hogger et al. 1995) 
and M5 receptors (Spalding et al. 1997). In these cases the muscarinic 
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antagonists atropine and 4-DAMP displayed inverse agonist function and 
were able to revert mutant receptor activity to that of the wild type. The 
detection of constitutive receptor activity has led to a refinement in the model 
of receptor activation. The receptor has been proposed to exist in two states; 
an inactive and active state that is able to interact with G proteins. Agonists 
are able to bind to the receptor and induce a conformational change in the 
receptor to the active state. However an antagonist needs to be classed as 
either a neutral antagonist which simply binds to the receptor and has no 
further effect other than to prevent an agonist from binding to that site or an 
inverse agonist which binds to the receptor but promotes a conformational 
change from the active to the inactive state. Kenakin in his review suggests 
that up to 85% of ‘antagonists’ can behave as inverse agonists (Kenakin 
2004). Constitutive receptor activity has recently been found to be a feature of 
number of pathological conditions. An example of this is Chagas disease, 
which is caused by the parasite Trypanosoma Cruzi. It has been suggested 
that infection results in the production of autoantibodies against the second 
extracellular loop of the M2 acetylcholine receptor, which decrease myocardial 
contractility and reduce cAMP production. There is subsequent 
desensitisation and internalisation of the receptor.  Constitutive activity has 
been demonstrated to occur due to genetic polymorphism; The S49G 
mutation in the β1-adrenoceptor, identified in patients with heart failure, 
appears to result in constitutive activity of the receptor and increased 
desensitisation. This SNP was beneficial to the patients, as long-term survival 
was significantly greater than in patients who possessed the wild-type 
receptor (Levin et al. 2002). 
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The classification of antagonists as either being neutral or inverse is likely to 
attain greater significance to the pharmacological industry as a disease 
caused by a constitutively active genetic variant of the receptor may respond 
only to an inverse agonist but not a neutral antagonist. Furthermore, a 
disease caused by over stimulation of the receptor by antibodies or excessive 
neurotransmitter release, may in theory, be better treated by a neutral 
antagonist, as these have been implicated to cause less receptor upregulation 
(Milligan, Bond, & Lee 1995). It has also been demonstrated that there may 
be more than one active state of the muscarinic receptor, which may be 
induced by different agonists. Akam and his colleagues demonstrated in 
Chinese Hamster Ovary cells expressing the M3 acetylcholine receptor that 
pilocarpine could induce a Gαi/0 response, whereas methacholine additionally 
produced a Gαq/11 response (Akam, Challiss, & Nahorski 2001). 
 
Receptor regulation 
Desensitisation of muscarinic receptors in response to acetylcholine is likely 
to occur in vivo as parasympathetic nerves exhibit tonic firing activity and this 
is likely to be part of a homeostatic mechanism, which regulates cellular 
function. The immense complexity and diversity of regulatory proteins which 
interact with muscarinic receptors is indicative of the wide range of 
physiological functions that are performed by the relatively few muscarinic 
receptor subtypes and tissue specific functionality is likely to be endowed by 
these regulatory processes. Phosphorylation of the muscarinic receptor is a 
key but not exclusive mechanism of receptor regulation (Willets et al. 2001). 
Multiple phosphorylation sites have been discovered in the third cytoplasmic 
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loop and the C-terminus of the muscarinic acetylcholine receptor involving 
serine and threonine residues (Pollok-Kopp et al. 2007) and occasionally 
tyrosine residues (Fan et al. 2001). 
 
Rapid receptor phosphorylation in response to agonist stimulation is a 
posttranslational modification adopted by nearly all G protein–coupled 
receptors (GPCRs) (Pierce, Luttrell, & Lefkowitz 2001). Several classes of 
kinase mediate muscarinic receptor phosphorylation. Amongst them are the 
GPCR kinases (GRKs), protein kinase C (PKC), casein kinase 1α (CK1α) and 
protein kinase C (PKC).   
The GRK family currently consists of seven proteins (GRK1- 7). GRKs only 
phosphorylate the agonist occupied receptor leading to the binding of 
arrestins, which suppress G protein interaction (Pierce, Luttrell, & Lefkowitz 
2001). GRK 2 and GRK 3 reside in the cytosol but translocate to the cell 
membrane in response to agonist activation of the receptor (Haga & Haga 
1992). GRK 2 and GRK 3 interact with βγ subunits of the G protein via a 125 
amino acid pleckstrin homology domain (Krupnick & Benovic 1998). In 
hippocampal neurons Willets and his colleagues concluded that endogenous 
GRK2 is a regulator of M1 mACh receptor signalling and that this process 
involves both phosphorylation-dependent and -independent mechanisms 
(Willets, Nahorski, & Challiss 2005). 
GRK5 and GRK 6 are ubiquitously expressed however it is not clear which 
receptors are their targets, though there is some evidence that M2 and M3 
receptors are targeted (Gainetdinov et al. 1999;Willets, Nahorski, & Challiss 
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2005). GRK phosphorylation can promote receptor activation of G protein–
independent pathways such as the MAPK cascade (Wei et al., 2003). 
It has been demonstrated that M1 and M3 but not M2 receptors are 
phosphorylated by PKC. In contrast to the actions of GRK, PKC acts in an 
agonist independent manner (Haga & Haga 1992).  
Casein kinase 1α has been shown to phosphorylate residues within the third 
cytoplasmic loop of the M3 acetylcholine receptor. However this does not 
seem to result in any desensitisation (Budd, McDonald, & Tobin 2000). 
Casein kinase 2 has been demonstrated to phosphorylate the M3 muscarinic 
receptor. This was shown to regulate the activation of Jun-kinase but not 
ERK1/2 and have no effect on Internalisation of the M3-muscarinic receptor 
(Willets, Nahorski, & Challiss 2005).  Furthermore this phosphorylation 
differed between cell types.  
Agonist induced activation of the muscarinic receptor leads to phosphorylation 
of residues within the third cytoplasmic loop of the muscarinic receptor and 
this facilitates internalisation of the receptor (Moro, Lameh, & Sadee 1993; 
;Pals-Rylaarsdam & Hosey 1997). However, agonist activation does not seem 
to be the only means of inducing phosphorylation as binding of the receptor 
with the inverse agonist N-methylscopolamine results in significant receptor 
internalisation (Vogler et al. 1998). GRKs play an important role in receptor 
internalisation, however this is very much receptor subtype and cell type 
specific. Studies on GRK knockout animals have suggested that a given 
receptor subtype expressed in different tissues may be phosphorylated by a 
different set of receptor kinases (Walker et al. 1999). Receptor 
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phosphorylation, desensitisation and internalisation do not correlate in all 
studies (van Koppen & Kaiser 2003).  
β-arrestin 1 and 2 can bind to the phosphorylated receptor (Goodman, Jr. et 
al. 1996) and also to clathrin which is a component of  the endocytic system. 
Expression with a β-arrestin 1 mutant which is unable to interact with the 
phosphorylated receptor demonstrate markedly reduced receptor 
internalisation of M1, M3 and M4 receptors in HEK293 cells (Goin & Nathanson 
2006). Similarly expression of a dominant negative clathrin mutant markedly 
reduces receptor internalisation of M1, M3 and M4 receptors (Vogler et al. 
1998). Some studies have concluded that M2 receptor internalisation may not 
be mediated by clathrin, as the M2 receptor does not appear to interact with β-
arrestin (Wu et al. 1997).  Internalisation of M2 muscarinic receptors via 
different mechanisms has been reported; Feron  reported that M2 receptors in 
cardiac monocytes can be internalised in caveolae which are invaginations of 
the plasma membrane (Feron et al. 1997).  However, a recent study in 
cardiac atrial muscle suggests that internalisation of the M2 receptor is 
mediated by β-arrestin 2 and clathrin and contributes to the desensitisation of 
the muscarinic K+ current (Yamanushi et al. 2007). Muscarinic receptor 
internalisation involves the interaction of other molecules such as AP-2, 
dynamin and the cytosolic binding protein c-Src. Expression of dominant 
negative forms of dynamin (Claing et al. 2000) and c-src  (Luttrell et al. 1999) 
demonstrate markedly reduced receptor internalisation. Heterodimerization 
has been implicated as a process that can influence receptor regulation as 
Goin and his colleagues have demonstrated that coexpression of M3 mAChR 
with increasing amounts of the M2 subtype receptor in JEG-3 cells resulted in 
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an increased agonist-induced down-regulation of M3 receptors (Goin & 
Nathanson 2006). 
 
Receptors, which have been internalised, can be resensitized. It has been 
proposed that the internalised receptor is dephosphorylated by a GPCR 
phosphatase in an endocytic compartment and subsequently recycled to the 
plasma membrane (Krueger et al. 1997). However internalisation of the 
receptor is not necessarily a prelude to resensitization (Tobin, Lambert, & 
Nahorski 1992)  and may lead to down regulation and attenuation of signalling 
(Krudewig et al. 2000). 
 
Conclusion 
Over the last ten years there has been rapid growth in our understanding of 
muscarinic receptor function. Understanding of tissue specific regulatory 
mechanisms may lead to the development of specific pharmacological 
interventions. Likewise, an appreciation of the subtle differences in function 
brought about by genetic polymorphism may lead to gene specific therapies. 
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1.3  Purinergic Receptors 
 
Introduction 
 
ATP is a neurotransmitter, which acts on purinergic receptors.  It has a wide 
range of functions within the mammalian peripheral and central nervous 
system. It is released often as a co-transmitter from many nerve axons 
including cholinergic, adrenergic, glutamergic and GABAergic nerve terminals 
(Zimmermann 2008) and also from non innervated tissue such as epithelial 
surfaces. There is evidence that altered purinergic signalling is present in a 
range of diseased states such as pulmonary hypertension (Sprague et al. 
2001), diabetic retinopathy (Sugiyama et al. 2004) and interstitial cystitis 
(Osterberg, Hallander, Kallner, Lundin, & Aberg 1991;Sun & Chai 2002). 
 
The purine receptor family (Appendix, Table 2, page 177) consists of P1 
receptors, which respond to adenosine, which is the final breakdown product 
of ATP hydrolysis, and P2 receptors, which respond to ATP/ADP. P2 
receptors are further classified as P2X receptor and P2Y receptors Currently 
molecular cloning has identified 4 P1, 7 P2X and 8 P2Y receptor subtypes.  
 
P2X receptors exist primarily as trimers (Nicke et al. 1998;Nicke 2008). Each 
receptor has seven subunits, only two of which are transmembrane domains 
(Zimmermann 2008). They function as ligand gated non-selective cation 
channels that allow the influx of Na+ and Ca2+ and efflux of K+. The P2X 
receptor can bind up to three ATP molecules and binding is believed to occur 
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between receptor subunits. P2X receptors 1 to 5 can form homo or 
heterotrimers whereas the P2X6 receptor forms only heterotrimers whereas 
the P2X7 forms only homomers. The properties of purinergic receptor trimers 
are influenced by their subunit composition. 
 
P2Y receptors like P1 receptors are members of the G protein coupled 
receptor super family. Structurally they consist of seven transmembrane α 
helical domains and function through activation of G proteins and intracellular 
secondary messengers and can be activated by a number of nucleotides and 
their degradation products (Appendix, Table 2). They have also been shown 
to activate ion channels (Hussl, Kubista, & Boehm 2007). 
A diverse range of enzymes of varying specificity can break down ATP 
released from cells. Membrane bound ectonucleotidases which have their 
catalytic subunit facing the extracellular space have been classified into two 
subfamilies;- the triphosphate diphosphohydrolases that hydrolyse nucleotide 
tri and di phosphate eg ATP conversion to ADP and ADP conversion to AMP 
and the pyrophospatase/ phospodiesterase which have lesser specificity and 
are able to convert ATP to AMP and cAMP to AMP. However a range of other 
enzymes contribute to ATP hydrolysis such as GPI-anchored alkaline 
phosphatases and the GP-anchored ecto-5-nucleotidases. 
Purinergic receptors are known to undergo rapid desensitisation in response 
to agonist stimulation occurring within seconds and taking up to fifteen 
minutes to recover. Differing rates of desensitisation have been noted 
between the receptor subtypes with the fastest rates of desensitisation 
occurring in P2X1 and P2X3 receptors (North 2002).  
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Detrusor Contractility 
Probing of the neurotransmitter mechanism activated by electrical excitation 
of detrusor smooth muscles from humans and animals have demonstrated a 
significant proportion of the elicited contraction being resistant to atropine. 
This proportion is low in normal human tissue (Burnstock 2007) but has found 
to be increased in a number of conditions including interstitial cystitis (Palea et 
al. 1993), obstructive (Bayliss et al. 1999) and overactive bladder symptoms 
(O'Reilly et al. 2001) consistent with a concept of neuronal plasticity. O’Reilly, 
in their study of the P2X receptor found that P2X1 was the predominant 
purinergic receptor subtype expressed at the mRNA level. However, all the 
remaining purinergic receptors were consistently expressed.  
Bayliss demonstrated that atropine resistance was not present in patients with 
urodynamically normal bladders in contrast to those with outflow obstruction 
and detrusor overactivity who had the greatest atropine resistance. 
Furthermore this atropine resistance could be abolished through the addition 
of ABMA, which effectively desensitises the purinergic receptor from 
producing further ATP mediated responses. However when exogenous ATP 
was added to muscle strips there was no significant difference in the potency 
of exogenous ATP in eliciting responses between the three patient groups. 
Furthermore there was evidence that ATP and acetylcholine were 
cotransmitted, on the basis of the similarity between the overall electrical field 
stimulation frequency response curve and the atropine resistant frequency 
response curve in that they had the same half maximal response frequency, 
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suggesting that acetylcholine and ATP were released from nerves that had 
the same excitatory potential, if not the same nerves. 
Harvey et al have found increased potency of ATP at initiating detrusor 
contractions in patients with detrusor overactivity may be due to decreased 
hydrolysis of ATP (Harvey et al. 2002).   
Neuronal plasticity has been demonstrated in animal models of outflow 
obstruction, where increased purinergic and decreased cholinergic signalling 
has been demonstrated in rabbits with outflow obstruction (Calvert et al. 
2001). However others have found decreased purinergic signalling in outflow 
obstruction (Scott, Uvelius & Arner 2004).  Whilst there are undoubtedly 
changes in purinergic signalling as a result of pathophysiology, whether this 
accounts for patient’s symptoms has yet to be determined. 
There is evidence for an increase in purinergic signalling in the human 
bladder with advancing age; the atropine-resistant component of nerve-
mediated contractions of the human bladder was found to be increased with 
age, principally as a result of increased release of ATP (Yoshida et al. 2004). 
The sensitivity of the bladder to the purinergic agonist αβ-meATP has been 
shown to increase with age (Wuest et al. 2005). However, there was no 
change in the mRNA detected for P2X1 and P2X3 in this study.  
 
ATP and the Urothelium 
There is growing evidence that the urothelium does not merely function as a 
barrier but has neuronal properties as demonstrated by its copious expression 
of neurotransmitter receptors and the host of chemical mediators that are 
released by the urothelium (Birder et al. 2002). 
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Stretch activated ATP release has been demonstrated from the urothelium of 
the bladder (Ferguson, Kennedy & Burton 1997) and also from the ureters  
(Burnstock 2002). The mechanism of ATP release from neuronal axons is 
believed to be exocytotic vesicular release however the mechanism of release 
form non-neuronal cells remains uncertain. A host of mechanisms accounting 
for this process have been proposed – vesicular release, connexin and 
pannexin hemi channels, ATP binding cassettes, P2X7 receptors (Burnstock 
2007). The basal and stretch activated (hypotonic stimulus) release of ATP 
from the urothelium of spinal cord injured rats is greater than controls 
suggesting a pathophysiological role in neuropathic detrusor overactivity. The 
stretch activated luminal but not serosal ATP release could be inhibited by 
botulinum toxin A suggesting a vesicular mechanism of release for stretch 
activated ATP release and an alternative mechanism for basal release (Khera 
et al. 2004). 
There is a growing body of evidence to suggest that ATP release from the 
urothelium is enhanced in a number of diseases and inflammatory states. 
Increased ATP has been found in patients with UTI (Osterberg, Hallander, 
Kallner, Lundin, & Aberg 1991) and interstitial cystitis (Sun & Chai 2002) and 
from rats with cyclophosphamide induced cystitis (Smith et al. 2005). Studies 
in P2X3 knockout mice have demonstrated bladder hyporeflexia and reduced 
response to pain (Cockayne et al. 2000). P2X3 receptors are expressed within 
the urothelium, the suburothelium and within nociceptive sensory neurons 
within the dorsal root ganglion (Andersson 2002). P2X3 receptors expression 
has been found to be upregulated in patients with interstitial cystitis (Sun & 
Chai 2002). ATP has been demonstrated to be independently released from 
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both the luminal and basolateral surface of the urothelium (Khera, Somogyi, 
Kiss, Boone, & Smith 2004). The question arises as to why ATP is released 
into the urine when the sensory nerves are located on the other side of the 
urothelium in proximity to the basolateral surface. One explanation is that 
there is increased leakiness of the urothelium and or umbrella cell death in 
diseased states.  There are several lines of evidence however that would 
point to an active physiological release mechanism instead. Firstly that basal 
release has been demonstrated in normal as well as pathological urothelium 
secondly that luminal release can be specifically inhibited by botulinum toxin A 
(Khera et al 2004; Somogyi et al. 2005) and depletion of intracellular Ca2+ 
stores (Van der Wijk et al. 2003) and lastly the resistance of the urothelium 
from spinal cord injured rats is not markedly different from controls (Apodeca 
et al. 2003) indicating that this urothelium is no more leaky in those with spinal 
cord injury though there is an increase in ATP release. 
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1.4 Ussing Chamber 
 
The Ussing chamber so named after it is inventor Hans Ussing, is a piece of 
apparatus that allows the selective perfusion of the apical and basal surfaces 
of an epithelial sheet, measurement of epithelial ion transport and the ensuing 
changes in its electrical properties. A wide range of applications have been 
developed for this versatile apparatus, such as measurement of drug 
absorption, tissue permeability and investigation of ion transport coupled 
/mechanosensory afferent mechanisms (Li, Sheppard, & Hug 2004). 
Functionally the apparatus consist of two units; a physical chamber for 
mounting and perfusing the tissue and an electrical circuit for recording 
epithelial ion transport and measuring the resistance of the tissue sample.  
 
Ussing Chamber Types 
There are two types of Ussing chambers; recirculating chamber and a 
continuously pefusing chamber. A recirculating chamber consist of a U tube 
which allows for equal column heights of solution being applied to each side 
of the urothelium so that the hydrostatic forces across the membrane can be 
balanced. Equalizing the hydrostatic forces across the membrane can reduce 
the risk of damaging the membrane and isolate the driving forces for transport 
across the membrane to electrico-chemical influences. Alternatively, adjusting 
the net hydrostatic forces can be used to explore mechano-sensory 
mechanisms and mimic hydrostatic pressures, which may exist within the 
lumen of visceral organs such as the bowel or bladder (Li, Sheppard, & Hug 
2004). The disadvantage of a recirculating Ussing chamber is that once a 
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reagent is added to the perfusing solution on either side of the Ussing 
chamber then it remains within the chamber. This inflexibility can be 
overcome by using a continuously perfusing system where reagents can be 
continuously added and washed out from either side of the tissue. The 
perfusing solution is amenable to warming via water jackets around the 
connecting tubing. 
 
Epithelial Electrical Properties 
Epithelial surfaces being transporting membranes have an asymmetrical 
distribution of ion channels between their apical or luminal surface and their 
basal or serosal surface. This results in the presence of a negative voltage at 
the apical surface in reference to the basal surface. This negative voltage is 
present whether the epithelium is secreting or absorbing ions or substrate. In 
theory the overall transepithelial voltage is a sum of apical and basal voltage 
differences. A well-studied example of a transporting membrane is frog skin. 
Here the apical surface can have a polarity of +60mV, this is generated by the 
movement of Na+ ions through open ion channels down their concentration 
gradient. At the basal membrane Na+ is actively transported against an ionic 
gradient by the Na+/ K+ ATPase ionic exchange transporter. Intracellular K+ 
concentration is maintained by the outward movement of K+ ions down a 
concentration gradient and hence transmembrane potential here is near the 
Nernst voltage for this ion i.e. –70 mV. Thus the sum transepithelial voltage 
from basal to apical is –70mV –(+60mV) =130mV (Nagel 1977). In practice 
this voltage is never actually measured because of the resistance of the ex-
vivo tissue and integrity of the membrane serves to diminish the recorded 
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value of measurements. Nonetheless useful measurements are possible by 
taking into account the direction of change of transepithelial voltage in 
response to selective ligands (fig 1d). 
 
Electrical Recordings 
The epithelium can be conceived of as a simple electrical circuit (fig 1e). 
The Ussing chamber is designed for making accurate electrical 
measurements. It is crucial that the epithelium is handled and dissected very 
gently so as not to disrupt its continuity. The epithelium is stretched tightly 
over an aperture, which is typically 2 –10 mm in diameter so as to produce a 
watertight seal that prevents the leakage of perfusing solution around the 
epithelial sheet.  Different methods have been utilised for securing the 
epithelium such as rubber rings, pins, histoacrylic glass or air suction.  Salt 
bridges are used to provide an interface between the electrical flux across the 
epithelial chamber and the measuring circuit. The AgCl /Agar KCl salt bridge 
is one of the most commonly used. The ideal electrode combines low 
resistance, reusability and minimal ionic leakage, which may affect or damage 
the epithelium. A KCl concentration of 0.5M to 3.0M is often used in the salt 
bridges. The higher the concentration of KCl used, the lower the resistance 
but the greater the risk from leakage of KCl to the epithelium. 
In order to measure the voltage across the membrane the electrodes are 
typically placed as close as possible to the membrane so as to reduce the 
resistance RC (Fig 1e). The electrodes measuring current can be placed 
further away than the voltage electrodes.  
 59
In order to calculate transmembrane resistance RTE, transepithelial voltage 
(TEP) and short circuit current (SCC) needs to be measured. Measurements 
can be made using open circuit or short circuit condition using voltage or 
current clamping. Voltage clamping involves applying fixed voltages across 
the membrane and measuring the resulting current. Current clamping involves 
injection of a small amount of current across the epithelium and measuring 
the resulting voltage changes. Estimation of resistance can be made by both 
of these methods using Ohms Law. Of the two modes of measurement 
current clamping produces a lesser perturbation of the cells as the current 
injected only produces a temporary change to the voltage across the 
epithelium. The TEP can be measured directly by a voltmeter during open 
circuit recording, and the SCC can be estimated from Ohms Law if either 
voltage or current clamping is used to measure epithelial resistance. 
Alternatively, the SCC can be measured directly during zero voltage clamping 
when the TEP voltage is clamped to zero volts through the injection of small 
amounts of current across the epithelium, which is regulated by a feedback 
amplifier. The resistance of the epithelium can again be derived using Ohms 
law through dividing the SCC into the TEP. This is conditional on the integrirty 
of the urothelium and there is thereby not another alternative route for the 
passage of current across the urothelium (Rs being large in Fig 1e) and there 
being a low resistance of the ex vivo circuit (RC being small in Fig 1e). In 
practice experimental conditions do not allow for accurate derivations of these 
values, but changes in these variables in response to specific ligands during 
the course of an experiment can yield useful information about epithelial 
transport mechanisms.
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 Fig 1d Transepithelial voltage across an epithelial surface 
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Fig 1e; Representation of measurements of epithelial electrical properties by a 
circuit diagram. RA is the apical membrane resistance and RB the basal 
membrane resistance. The sum of these two values is RTE the transepithelial 
resistance. The difficulty in measuring this absolute value and the voltage and 
current across the epithelium is illustrated by two further resistances. RS is the 
shunt resistance, which represents an alternative route for current either 
through a hole in the epithelium or around the edge and ideally should be as 
large as possible. RC is the resistance of the exvivo circuit consisting of the 
electrodes, wiring and salt bridges.  If RC is large in relation to the resistance 
of the voltmeter then the voltmeter underestimates the voltage across the 
urothelium as there will be a significant potential drop dissipated across RC. 
Most voltmeters are of very high resistance nonetheless and the resistance of 
RC is usually insignificant compared to the resistance of the voltmeter. 
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Chapter 2 
 
Methods 
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2.1 Patient recruitment 
 
Patients undergoing open bladder surgery, general anaesthetic cystoscopy or 
flexible cystoscopy were recruited to the study with ethical approval (from the 
Whittington and Moorfields Research Ethics Committee) and informed 
consent. Patients were classified according to their urinary symptoms in 
accordance with the International Continence Society classification; 
 
Normal
 (No urgency and urinary frequency < 8 per day and nocturia < 2 per 
night. 
Overactive Bladder Symptoms
 (Urinary urgency ± frequency (>8 voids per 
day) ± nocturia (>2 voids per night), without a known neurological aetiology. 
Neuropathic
 
overactive bladder symptoms (Neurological diagnosis for 
OAB as defined above. 
Outflow Obstruction Undergoing TURP or have an enlarged prostate on 
cystoscopy with IPSS score >7. 
 
The admissions lists and waiting lists were obtained each month. Patients 
who were on the waiting list, to undergo a rigid cystoscopy, flexible 
cystoscopy, TURP, TURBT, open cystolithopaxy, cystectomy and CLAM 
ileocystoplasty as part of their clinical management were written to with a brief 
lay description of the study asking whether they would be willing to consider 
helping. A prepaid reply envelope was enclosed along with instructions on 
how to respond should they be willing to consider providing a bladder biopsy 
for research purposes during the procedure. 
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The details of patients who made an affirmative response were recorded on a 
separate database.  Where a patient agreed to provide a biopsy, they were 
sent a full information sheet and arrangements were made for them to sign a 
consent form. The usual preoperative assessment was arranged at this 
attendance. The admission date for biopsy was recorded in the study-
monitoring diary. The study instructions relevant to the surgical team were 
placed in the hospital notes along with a copy of the consent form.  
At the time of admission to the day-care unit the surgical staff were warned of 
the need for a research-related tissue biopsy and the appropriate preparations 
were effected. The patient’s willingness to provide a gift of a tissue biopsy was 
re-confirmed at the time of this admission by the supervising clinician. 
The biopsy sample was collected according to the instructions, which were 
placed in the medical notes. The collection of the specimen and the reception 
by the research team was recorded in the hospital notes. The investigator 
signed the study patient completion page and this was documented in the 
hospital notes. 
 
A single research biopsy was taken from the dome of the bladder and stored 
in iced, calcium-free HEPES solution, buffered at pH 7.2 (mM): NaCl 105.4, 
NaHCO3 22.3, KCL 3.6, MgCl2 0.9, NaH2PO4 0.4, HEPES 19.5 , glucose 5.4 , 
Na pyruvate 4.5, and experiments were commenced within one hour of 
collection.  
Full thickness samples were taken from patients undergoing open bladder 
surgery and these samples were used for organ bath experiments where 
large samples were necessary in order for strips to be cut. 
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Cystoscopic samples were used for the dispersed detrusor cell experiments. 
 
2.2 Animal Tissue Preparation 
 
 
Guinea pigs 
 
Male Duncan Hartley albino guinea pigs, weighing between 300-450 g were 
weighed and sacrificed using cervical dislocation or CO2 asphyxiation. The 
bladder was promptly dissected and removed prior to storage in a calcium 
free physiological solution (Appendix 1 for organ bath work and Appendix 2 
for isolated detrusor experiments) and transported on ice to the laboratory. 
 
Rat 
Male rats weighing 300 – 350g were weighed and sacrificed using CO2 
asphyxiation. The bladder was promptly dissected and removed prior to 
storage in a calcium free physiological solution (Appendix 2) and transported 
on ice to the laboratory. 
 
Bladder preparation 
The bladder was incised longitudinally, opened out and mounted under slight 
stretch on an agar dish using hypodermic needles. The urothelium was 
dissected away as a single sheet from the underlying detrusor muscle under 
direct microscopy (x 10 magnification) using blunt dissection with a pair of 
scissors taking care not to perforate the urothelium.  
The urothelium was used for Ussing chamber experiments (section 3).  
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2.3 Detrusor organ bath experiments 
 
Detrusor muscle strips were cut parallel to the orientation of the muscle fibres 
from the denuded bladder under direct light microscopy (x10 magnification). 
Strips were approximately 7-10mm in length and 1mm in width. The detrusor 
strips were fixed, in a superfusion trough, at one end to a hook and the other 
to an isometric force transducer (Fig 2A). The tissue was superfused with 
Tyrode’s solution (mM): NaCl 120, NaHCO3 24, KCl 4, CaCl2 1.8, MgCl2 1, 
NaH2PO4 0.4, glucose 6.1, Na pyruvate 5, at 37°C with 95% O2-5% CO2, pH 
7.4, at 2 ml/minute for 3 hours to ensure equilibration prior to experimental 
recordings taking place.  During this time contractions were generated by 
electrical field stimulation (EFS:  8 Hz, 3 s trains, 0.1 ms pulse width). When a 
consistent response was established, dose-response curves were constructed 
for either carbachol (≤100 µM) or oxotremorine (≤10 µM). All dose response 
curves were generated by a 3 minute exposure of the agonist at 2ml/minute 
with a subsequent 30 minutes washout period with tyrodes solution during 
which tension was seen to return to baseline levels prior to progression with 
the subsequent agonist concentration. EFS responses were elicited between 
1 and 80 Hz. The selective M2 antagonist methoctramine and gallamine 
(Sigma Aldrich Companies Limited) and the M3 antagonist, 4-DAMP (Sigma 
Aldrich Companies Limited) were tested on different strips. They were added 
to the superfusate for 30 minutes after, which agonist responses and EFS 
were retested as described above. This sequence was repeated for 
increasing concentrations of antagonist (Fig 2B). On completion of the 
experiments the detrusor strips were weighed and their length measured. 
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From these two values an estimated cross sectional area for each strip was 
calculated. The muscle was assumed to have a density of 1g/cm3. Human 
detrusor strips were tested in tandem where sequential dose response curves 
were generated as described above in the absence of any antagonist to 
ensure that there was no significant desensitisation of the tissue during the 
course of an experiment. 
Analysis; the peak force generated during a contraction was measured. A 
pEC50 value was calculated for each strip by curve fitting to the Hill Equation 
(Kaleidagraph, version 3.5, Synergy Software). For the purpose of curve fitting 
an assumption of competitive antagonism was made. The maximum was fixed 
and the slope set as nH =1. The pKB value for each antagonist was calculated 
for each strip via a Schild plot when methoctramine was used as the 
antagonist. The shortened schild equation (log [antagonist] – log [dose ratio – 
1]) was used to calculate the pKB when 4DAMP or gallamine were the 
antagonist.  
The overall pKB for each antagonist was taken as the mean of the derived pKB 
from each strip. The plotted points on the dose response curves shown 
represent the mean percentage of maximum contraction at a given agonist 
and antagonist concentration. The summary Schild plots were derived by 
calculating the mean dose ratio obtained on muscle strips for each given 
antagonist concentration. Significance between data sets was assessed with 
an unpaired t-test and statistical significance was taken as p<0.05. Scatter 
plots comparing variables obtained from the same muscle strip were analyzed 
using linear regression (Kaleidagraph, version 3.5, Synergy Software) and 
statistical significance was tested by ANOVA.   
 68
Fig 2A Organ Bath 
Fig 2B Experimental Design of Agonist/ Antagonist Experiments 
 
 
Tyrodes 
Antagonist 
Concentration 1  
Antagonist 
Concentration 2 
2nd Antagonist 
                             ↓   ↓            ↓ ↓        ↓ ↓      ↓ ↓ 
Agonists- 3 min perfusion, 30 mins washout 
 3hr equilibration →  
30 mins 
30 mins 
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2.4 Single cell detrusor experiments 
The following solution was used for the dispersion of detrusor cells 
 
Calcium free Dispersion Physiological Salt Solution (DPSS): 
 
Salt Concentration (mM) g/L 
Sodium Chloride (NaCl) 126 
 
7.36 
Potassium Chloride 
(KCl) 
6 0.45 
Magnesium Chloride 
(MgCl2) 
1.2 1.2ml from 1M stock 
Hepes 10 2.4 
Glucose 11 2.0 
 
pH made to 7.2 with 10M stock Sodium Hydroxide (NaOH). 
 
Dispersion: 
 
Material all obtained from Sigma-Aldrich. 
 
 
• The urothelium was dissected off the bladder sample to leave the 
smooth muscle layer. 
• The smooth muscle was cut into 0.5mm x 0.5mm pieces using sharp 
dissection. 
• Enzyme dispersal solution was made up in 10ml DPSS, consisting of 
10mg papain, 15mg collagenase type 1A, 50mg Bovine serum albumin 
(BSA), 2.5 mM Dithiothreitol (DTT).  
• Smooth muscle pieces were added to a glass vial with enzyme 
dispersal solution and incubated for 30mins at 37oC. 
• The smooth muscle pieces were removed from solution and washed 
for 5 mins in DPSS.  Repeated in fresh DPSS for a further 5 mins. 
• Sample left to stand for 10 mins at room temperature. 
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• The tissue was dispersed using 2 different wide bore Pasteur pipettes.  
Starting with widest to loosen up tissue and then moved on to smaller 
one to break up individual cells. 
• The dispersed myocytes were centrifugated at 13000rpm for a short 
pulse 
• 20µl cell suspension were pipetted onto polylysine slide. Each slide 
was used to test a different experimental condition. An aliquot of cells 
were pipetted onto a haemocytometer slide  (see figure 2c, page 61) 
for assessment of cell counts. Cells were stained with an equal volume 
of trypan blue for assessment of their viability. 
• 20µl of DPSS solution containing variable concentrations of Ca2+ (0-
1mM were added to the cell suspension and the cells were allowed to 
equilibrate on the slides for an hour. During this period they were kept 
at 0°C in a humidified container.  
• 20µl of DPSS solution containing the same concentration of calcium 
and a variable concentration of pharmacological agent was added to 
each slide. 
• The experiment was terminated through the addition of 1% acroelin. 
Experiments with rat detrusor were terminated after 30 seconds whilst 
experiments with guinea pig and human detrusor were terminated after 
3 minutes. 
• Coverslips were added to the slides. The edge of the coverslips was 
sealed with nail varnish. 
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Figure 2c Haemocytometer grid 
 
1mm 
The haemcoytometer grid depicted above was used to count 
muscle cell numbers. The area of the grid above is 9mm2. The 
chamber overlying the grid has a depth of 0.1mm therefore the 
total volume of the chamber is 0.9mm3 or 0.9µl. 
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Data analysis  
Digital photographs were taken of isolated cells under x 200 optical 
magnification using a Nikon 4500 camera. The aim was to include at least 100 
cells per slide.  For photographs the flash was turned off, the camera was set 
to focus to infinity and the maximum optical zoom was applied. The 
microscope was used to focus the image on the camera viewfinder prior to 
capture. A photograph of a 2mm graticule at x200 magnification was taken at 
the same camera setting. 
Images were transferred from the camera to PC by a USB connection and 
opened and analysed using image J software (NIH laboratories). 
Individual detrusor cells were identified by their long spindly and undulating 
appearance and were digitally measured using a segmented line.  
These cell lengths were copied to an Excel spreadsheet and converted to an 
actual length using a graticule measurement for reference. 
Cell lengths were analysed by PRISM 3.0 to assess their distribution, mean 
and SEM for statistical analysis. Differences were compared between groups 
using the student t test and statistical significance was taken as p ≤0.05.  
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2.5 Urothelial Ussing chamber experiments 
The opened bladder biopsies were placed mucosal surface up onto a petri 
dish and the entire sheet was secured under slight tension using 18g 
hypodermic needles. The edge of the urothelium was picked up using a pair 
of forceps and gently dissected way from the detrusor layer. 
The urothelium was placed between the two Perspex halves of a 0.35mm 
lumen Ussing chamber (USS2S - Small Chamber manufactured by World 
Precision Instruments). The urothelium was orientated such that the luminal 
surface was facing the V1 test electrode and the basolateral surface was 
facing the V0 (zero potential reference electrode). 
The voltage electrodes were placed in close proximity on either side of the 
urothelium and the current electrodes further away (see figure 2d). 
 
Construction of voltage electrodes. 
The voltage and current electrodes salt bridges were prepared in the same 
manner. A mixture of 0.5mM KCl and agar was made and this was warmed in 
a water bath to 80°c. The heated mixture was poured into the perspex 
electrode and allowed to cool and set hard. The salt bridge electrodes were 
stored in 0.5 mM KCl solution containing a silver pellet. 
For experiments, the agar filled salt bridges were secured onto the correct 
port of the Ussing chamber. The luer tipped electrodes were secured into the 
salt bridges and connected to the amplifier. 
The urothelium was allowed to equilibrate for two hours. During this period 
each surface of the urothelium was independently perfused at the same rate 
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under a gravitational generated pressure gradient with tyrodes solution 
containing 95% O2 , 5% CO2 at 37°C . A World Precision Instruments  
DVC1000 – Two channel Voltage/Current clamp with timer function was 
utilised. During equilibration the voltage clamp was set to passively measure 
the voltage across the urothelium. 
 
After equilibration the voltage clamp was set to cycle every 2.5 seconds 
between voltage and current clamping. During voltage clamping, the clamp 
potential was set to zero volts and current measurements were taken. During 
current clamp, the clamp current was set to zero and the potential difference 
was measured. Continuous voltage and current readings were fed from the 
voltage clamp to a chart recorder set at 30cm/hr and to an oscilloscope to 
observe the signal waveform. 
During experimentation, pharmacological agents were independently added to 
the tyrodes solution perfusing each surface of the urothelium. The new 
perfusing solution was introduced without introducing bubbles into the tubing 
by switching to a new perfusing chamber controlled by a 3 way tap (diagram 
3). Each agonist was added to the urothelium for a period of 10 minutes prior 
to switching back to tyrodes solution for a half hour washout. Agonists were 
added sequentially starting with the lowest solution prior to the addition of any 
antagonists. 
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Fig 2d Arrangement of electrodes across the Ussing chamber. 
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Chapter 3 
 
Results 
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3.1 Organ Bath Experiments- Human Detrusor. 
 
Twelve patients were recruited to the study. Five of these had neuropathic 
overactive bladder and seven patients had an overactive bladder.  Those with 
neuropathic bladder were undergoing CLAM augmentation cystoplasty (This 
procedure involves anastomosing small bowel on to the bladder to increase 
reservoir capacity and reduce voiding pressures). The overactive bladder 
biopsies came from patients undergoing either CLAM augmentation 
cystoplasty or cystectomy for cancer who described overactive bladder 
symptoms in accordance with the ICS definition. All biopsies were taken from 
the dome of the bladder.  
 
 
Patients; Table 4 shows a summary of study patient details. The mean age 
was 45.6, ranging from 19 to 70 years of age. Four patients were male and 
eight were female. The mean age of the neuropathic patients was 32 and the 
overactive patients 53. The difference was not statistically significant. 
Likewise none of the other variables in table 4 differed significantly between 
neuropathic and overactive patients; therefore the data were pooled for 
analysis. 
Contractile characteristics; The contractility of bladder strips was determined 
by taking the force generated by 100µM Carbachol divided by the cross 
sectional area of the strip, expressed as millinewtons mm-2 (mN mm-2). The 
mean value obtained for contractility was 24mN mm-2 but there was wide 
variability. 100 µM carbachol and 10µM oxotremorine produced maximal 
contractions of indistinguishable amplitude (percentage difference in mean 
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force = 6.6% ±10.6% SEM). The pEC50 value (mean ± SD) obtained for 
carbachol and oxotremorine induced contractions were not significantly 
different; 5.8 ± 0.4 (n=15) strips and 6.1 ± 0.51 (n=7) strips respectively.  
Figure 3.0 shows an example of dose responses achieved by varying the 
doses of carbachol. 
 
Repeated dose response curves (n=5) generated by carbachol did not show 
any significant change in EC50 and therefore there was no evidence of tissue 
desensitisation during the experimental protocol described (Fig 3.1). 
 
M2 inhibition; Dose-response curves were constructed for carbachol agonism 
in the presence of the M2 inhibitor methoctramine at concentrations ranging 
from 10 -1000 nM (Figure 3.2). Schild plot analysis produced a pKB value for 
methoctramine of 8.2 ± 0.3, against carbachol-induced contractions, which is 
compatible with M2 inhibition (Fig 3.2b). M2 inhibition was also tested using 
the allosteric inhibitor gallamine (Fig 3.3). The pKB for gallamine against 
carbachol-induced contractions was derived by the shortened Schild equation 
and was 5.87 (n=2). This value is compatible with M2 inhibition. Methoctomine 
was used to antagonise oxotremorine mediated contraction (Fig 3.4) and a 
pKB value of 8.26 ± 0.7 was derived, again compatible with M2 inhibition (Fig 
3.4b) 
 
M3 inhibition; Similarly 4-DAMP was used to antagonize carbachol and 
oxotremorine contractions (Fig 3.5 and 3.6). The pKB value for 4DAMP was 
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8.80 ± 0.4 against carbachol induced contractions and 9.8 ± 0.6 against 
oxotremorine contractions (analysis by shortened Schild equation). 
 
Electrical Field Stimulation (EFS); In all strips the maximal response produced 
by EFS (60 Hz) was significantly less than that achieved by 100 µM carbachol 
(49% ± 16%) (Fig 3.7a). Increasing concentrations of methoctramine 
produced dose-dependent reduction of EFS force (Fig 3.7b). 10nM 
methoctramine produced a mean reduction in force of 64% at 4 Hz, 40% at 8 
Hz and 34% at 40 Hz (p< 0.05 in all cases). 
 
 
Association between agonist potency and M2 activity. The potency of 
oxotremorine as determined by pEC50 values was significantly associated with 
the pKB values obtained for methoctramine against oxotremorine (p<0.05, Fig 
3.8). A similar comparison for carbachol points to the same trend though 
statistical significance was not achieved. 
 
Age related trends; With increasing patient age, there was reduced agonist 
potency of oxotremorine (Fig 3.9b) and EFS became less effective at 
producing a response relative to the agonist (Fig 3.9d), p< 0.05 in both cases. 
There was a trend for reduced contractility (Fig 3.9a) and reduced pKB of 
methoctramine for oxotremorine (Fig 3.9c), and increase in the half maximal 
frequency of stimulation (Fig 3.9e), though not statistically significant.  These 
trends need to be treated with caution as the sample small sizes are small 
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and patients with neuropathic OAB are often (though not significantly so in 
this data set) younger. 
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Table 4: Summary statistics from human bladder strips. 
Carbachol Contractions Oxotremorine Contractions 
             
EFS 
MAX% 
 
Diagnosis 
 
Patient 
no 
 
Gender 
 
Age 
Max 
force 
mN/mm2 
pEC50  pKB Meth  pKB 4DAMP   
 
pKB 
Gall pEC50  
pKB 
Meth  
pKB 
4DAMP    
Neuropathic 1 M 20 10.5 5.63 8.29   6.26 8.13 9.7  
 2 F 65 22.1 5.36    5.37 7.31   
 2 F 65 8.5 5.52 8.45       
 3 F 19 1.4 5.52 8.15   6.02 8.13   
 4 F 25 50.4     6.63 9.26 9.64 68 
 4 F 25 96.1     6.69 9.24  74 
 5 F 31 2.20 5.66 7.99 8.73  6.19 8.15  40 
 5 F 31 36.7 5.7        
Mean   32 28 5.6 8.2 8.73  6.2 8.4 9.67 60.6 
SD   19.1 32 0.12 0.20   0.48 0.75 0.04 18.1 
             
Overactive 6 F 43 70.9 5.73 7.81 9    9.22  
 7 F 36 9.3 5.97 8.04 8.3    10.7  
 8 M 61 9.8 5.4 8   5.5 8.02   
 8 M 61 11.6 5.43 7.95       
 9 F 42 30 5.87 8.45 8.88     56 
 10 F 66 21.4 6.8       33 
 11 M  2.7 6.71 8.61       
 12 M 70  5.97   5.6    36 
 12 M 70 0.3 5.87   6.14    37 
Mean   54.6 19.5 5.97 8.14 8.73 5.87 5.5 8.02 9.96 40.5 
SD   14.3 23 0.49 0.31 0.37    1.04 10. 
             
Overall             
Mean   45.6 24 5.8 8.2 8.7 5.87 6.1 8.3 9.8 49.1 
SD   19.3 27 0.43 0.26 0.31  0.51 0.70 0.63 16.7 
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Fig 3.0; Agonist responses recorded from a human detrusor strip. 
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Fig 3.1 Repeated Carbachol dose response curves in the absence of an 
antagonist (n=5). 
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Fig 3.2a Methoctramine antagonism of carbachol induced contractions (mean 
±SEM, n=15 muscle strips) and Schild plot, Fig 2b pKB=8.20, Hn =0.54. 
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Fig 3.3a Gallamine inhibition of carbachol induced contractions (n=2), 
pKB=5.8 by shortened Schild equation. 
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Fig 3.4a Methoctramine inhibition of oxotremorine induced contractions (mean 
±SEM, n=7) and Schild plot Fig 3.4b pKB=8.4, Hn =0.85, N=7. 
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Fig 3.5; 4 DAMP inhibition of carbachol induced contractions (mean ± SEM, n=3), 
(pKB by shortened Schild equation=8.80. 
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Fig 3.6, 4 DAMP inhibition of oxotremorine induced contractions (mean ± 
SEM, n=4).  
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Figure 3.7a. EFS frequency responses expressed as a proportion of contractions 
produced by 100µM carbachol (n=8, mean ± SD). Fig 3.7b the effect of increasing 
concentrations of methoctramine on EFS at 4, 16 and 40 Hz (n=5, mean ± SD, 
force as a percentage of 100 µM carbachol contraction). 
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Fig 3.8. Agonist potency versus pKB of methoctramine. R=0.90 for 
oxotremorine contractions. R=0.56 for carbachol contractions. 
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Fig 3.9. Age related trends in muscarinic activity; a) contractility, maximum force 
per cross sectional area generated by 100µM carbachol (n=15). b) Potency of 
oxotremorine (n=7, r=0.84, p<0.05). c) pKB of methoctramine with oxotremorine 
(n=7, r=0.61).d) Change in EFS maximum response relative to 100µM carbachol 
(n=7, r=0.80, p<0.05). e) Frequency that produces half maximal response f50. 
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3.2 Organ bath experiments- Guinea Pig detrusor 
 
The Guinea pig detrusor strips produced maximal contractions in response to 
100µM Carbachol, with an average force per unit cross sectional area of 19.1 
mN/mm2 but there was wide variability – 3.78 to 66.6 mN/mm2. 10uM 
Oxotremorine similarly elicited maximal contractions (96.6% ± 4.6% of that 
elicited by 100µM Carbachol, n=7). However, carbachol was a significantly 
less potent agonist than oxotremorine (mean ± SD; pEC50 = 5.34 ± 0.29 
(n=19) and pEC50 = 6.39 ± 0.53 (n=7) respectively, p<0.05, Figure 3.10).  
M3 inhibition of carbachol contractions. Carbachol contractions could be 
competitively inhibited by the addition of the M3 preferential antagonist 4 
DAMP (Fig 3.11). An experimental pKB of 8.6 ± 0.46 (n=7) with Hn = 1.16 was 
obtained.  
M2 inhibition of carbachol contractions. Carbachol contractions could not be 
competitively inhibited by either of the two M2 antagonists, gallamine or 
methoctramine (Fig 3.12 and Fig 3.13), 
M2 inhibition of oxotremorine contractions (Fig 3.14); Oxotremorine 
contractions were inhibited by the M2 antagonist methoctramine. Near 
maximal inhibition was achieved with the lowest dose of inhibitor utilized. 
Results from shortened Schild plot analysis produced a pKB of 8.57 ± 0.45. 
Electrical Field Stimulation (EFS); Electrical field stimulation produced 
contractions that were on average 91.6% ± 9.7% of the maximal contraction 
that were achievable by 100µM Carbachol (Fig 3.15).  
EFS inhibition with methoctramine; Methoctramine inhibited EFS as shown in 
Fig 3.15. 10nM - 1000nM had no effect on contractions elicited at 4Hz 
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frequency.10000nM reduced contractions by 68.4% from control. At 16hz and 
40HZ frequency EFS was significantly reduced by all concentrations of 
methoctramine of 100nM and above (30.3% and 15.6% reduction with 100nM 
methoctramine at 16 and 40Hz respectively, p<0.05).  At low frequency of 
stimulation ATP may have been the predominant neuro transmitter released 
and hence the relative ineffectiveness of M2 inhibition. At higher frequencies 
there is greater likelihood of direct stimulation of the muscle by the electrical 
field stimulation and hence the reduced effectiveness of M2 inhibition again. 
EFS inhibition with 4DAMP (Fig 3.16). At 4Hz stimulation, 4 DAMP at 
concentration up to 100nM did not produce any significant inhibition of EFS. 
3nM 4 DAMP significantly reduced contractions elicited at 16Hz and 40Hz 
(36.7% and 14.4% respectively). Like the experiments with methoctramine, at 
low frequencies 4DAMP had diminished effect, likely to be caused by the 
decreased cholinergic component to neurotransmission at lower frequencies. 
At higher EFS frequencies, there is increased direct stimulation of the muscle 
tissue as demonstrated by increased Tetrodotoxin (TTX) resistant component. 
(TTX leads to abolition of neurotransmitter release). 
Inhibition of Carbachol and Oxotremorine Contractions with forskolin (Fig 3.17 
and Fig 3.18); 10µM Forskolin had no effect on carbachol induced 
contractions either when utilized in isolation or in combination with 10nM 
Methoctramine. However, 10µM Forskolin significantly inhibited oxotremorine 
contractions (Fig 3.18). This inhibition was indistinguishable from that 
achievable by a 10nM Methoctramine or a combination of 10µM Forskolin and 
10nM Methoctramine; (pEC50 ± SD; Control 6.5 ± 0.28, 10µM Forskolin 6.03 ± 
0.15, 10nM Methoctramine 5.93 ± 0.15, 10nM Methoctramine + 10µM 
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Forskolin 6.02 ± 0.17). This suggests that methoctramine and forskolin are 
acting by, and saturating the same mechanism to produce inhibition of 
contractions, namely cAMP elevation. 
Combined antagonism of carbachol with 4DAMP and gallamine (Fig 3.19 and 
Schild plot Fig 3.20). Although gallamine had no effect on carbachol induced 
contractions when applied in isolation, when combined with 4DAMP it seemed 
to moderate the inhibition to a degree. At a concentration of 10µM gallamine, 
4DAMP inhibition was slightly attenuated at pKB=7.95 Hn=1.15 versus 
pKB=8.6 Hn=1.34 when 4DAMP was used in isolation. At a higher 
concentration of 100 µM gallamine, gallamine seemed to synergise 4DAMP 
inhibition with a pKB=9.96 Hn=0.5. 
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Fig 3.10 Carbachol and Oxotremorine Dose response in Guinea pig detrusor. 
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Fig 3.11; The effect of 4 DAMP on Carbachol induced contractions (n=7) pKB 
=8.6, Hn=1.15. 
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Fig 3.12; The effect of gallamine on carbachol induced contractions (n=7). 
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Fig 3.13. The effect of methoctramine on Carbachol Contractions. 
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Fig 3.14a Methoctramine inhibition of oxotremorine induced contractions. 
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Fig 3.14b Schild analysis of methoctramine inhibition of oxotremorine induced 
contractions, pkb=8.57 ± 0.45 (SD) by shortened schild equation. 
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Fig 3.15; Effect of methoctramine on EFS (n=6). 
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Fig 3.16; The effect of 4DAMP on EFS (n=6). 
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Fig 3.17 The effect of forskolin on oxotremorine contractions (n=5). 
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Fig 3.18; The effect of forskolin on carbachol contractions (n=4). 
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Fig 3.19; Combined antagonism of gallamine and 4-DAMP. 
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Fig 3.20 Schild plot of the antagonism of carbachol with 4DAMP in the 
absence of gallamine, the presence of 10µM gallamine and 100µM gallamine.  
pKB=7.95 Hn=1.15, pKB=8.6 Hn=1.34 and pKB=9.96 Hn=0.5 respectively. 
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3.3 Isolated detrusor cell experiments 
Fig 3.21 shows a typical micrographic image of isolated human detrusor 
myocytes, obtained from a patient with overactive bladder symptoms.  
Typically cell counts of over 100 were sought for each experimental condition. 
The micrograph demonstrates the variability in length and girth of isolated 
mycocytes and hence the need for large sample sizes. Figure 3.22 shows rat 
detrusor myocytes stained by H+E (x400 magnification).  
 
Figure 3.23 shows a comparison of detrusor cell lengths between human, 
guinea pig and rat detrusor tissue carried out in the absence of Ca2+. Values 
are shown on a relative scale but demonstrate that cell lengths were normally 
distributed. Guinea pig cells (mean ± sem = 258 ± 11) were significantly 
longer than rat cells (223 ± 11), which were significantly longer than human 
cells (193 ± 8), all p<0.05. 
 
Figure 3.24 demonstrates the effect of altering [Ca2+] between 0 and 0.5mM 
on resting cell lengths. An increase of [Ca2+] to 0.25mM and 0.5mM results in 
a significant shortening of resting cell lengths from 248 ± 11 to 198 ± 9 
(relative units p<0.05). 
 
Figure 3.25 demonstrates carbachol dose response curves carried out in rats 
(n=3). A pEC50 of 6.1 was obtained which is slightly lower than that obtained 
in organ bath experiments pEC50 = 5.34 ± 0.29 albeit in the guinea pig. 
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Figure 3.26. Methoctramine inhibition of carbachol mediated contractions in 
the presence of 0.5mM Ca2+ (n=1). A pKB of 9.23 was obtained, however, the 
plot does not demonstrate parallel shift that would be indicative of competitive 
inhibition. 
 
Figure 3.27; Oxotremorine dose response curves (n=2) carried out in the 
presence of 0.5mM Ca2+. The greatest degree of muscle cell relaxation was 
obtained in the presence of 0 mM Ca2+ and 10-5 M Ca2+ channel blocker 
nicardapine, perhaps indicating the presence of Ca2+ ions in the dispersal 
solution that have arisen from an intracellular source either due to trans 
membrane efflux or cell lysis as a result of the dispersal process or perhaps 
due to contaminants in the solution. 
 
A comparison between carbachol (n=3) and oxotremorine (n=2) dose 
response curves in the rat detrusor is shown in figure 3.28. Oxotremorine was 
slightly more potent pKB=6.21 versus 5.05. This is a similar trend to that which 
was established in organ bath experiments both in human and guinea pig 
detrusor strips. 
 
Human detrusor experiments: Carbachol dose response curve in 0.5 mM Ca2+ 
and 0.5mM Ca2+ and 10nM methoctramine (Figure 3.29, n=1, patient 
symptomatic with OAB). pKB =5.68, this was very similar to the value 
previously obtained with organ bath experiments of 5.8 ± 0.4). However, no 
evidence of M2 inhibition was manifest in this patient, as 10nM methoctramine 
did not produce any discernable shift in the dose response curve. 
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Figure 3.30 shows the resting and contracted detrusor cell lengths from 26 
patients who provided cystoscopic biopsies. All experiments were carried out 
in 0.5mM ca2+. The resting length was determined when no other drug was 
added. The fully contracted length was determined by the addition of 100 µM 
Carbachol. Patients with outflow obstruction had significantly longer resting 
cell lengths than OAB patients and controls (mean ± sem; 64.6. ± 1.45, 56.5 ± 
1.67 and 48.6 ± 1.67 respectively). Patients with OAB showed a decreased 
contractile response with carbachol indicating that patients with OAB may 
either contract less or have a higher resting tone i.e. the resting muscle cell 
length was precontracted and closer to the fully contracted state but this 
needs to be confirmed through relaxing the muscle with antagonists. 
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Fig 3.21 Micrograph of human detrusor cells (unstained) and graticule x200 
magnification.  
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Fig 3.22 gram stain of rat detrusor cells, x 400 magnification (carried out by 
Linda Churchill). 
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Fig 3.23. Comparison of the resting detrusor muscle lengths between human, 
guinea pig and rat tissue (carried out by Sebastian Clark).
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Fig 3.24. The effect of increasing Ca2+ concentrations on detrusor cell length 
(carried out by Sebastian Clark).
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Fig 3.25 Carbachol dose response curve in rat detrusor tissue (n=3, mean ± 
sem, fit to raw data) EC50 =6.1. 
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Fig 3.26  
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Fig 3.27 the effect of Ca2+ and Oxotremorine dose response in the presence 
of 0.5mM Ca2+ in isolated rat detrusor cells (n=2). 
 
 
 
 
 
 
Fig 3.28 Comparison of carbachol dose response (n=3) and oxotremorine 
dose response (n=2). 
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Fig 3.29 Carbachol dose response curve ; control and in the presence of 10 
nM methoctramine. 
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Fig 3.30 Evidence of detrusor muscle plasticity in outflow obstruction. 
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3.4 Ussing chamber experiments 
Purinergic and muscarinic function 
Measurement of baseline electrical properties; The baseline transepithelial 
potential (TEP), short circuit current (SCC) and conductance were measured 
as shown in Figure 3.31. 
Baseline measurements (n = 56 guinea pigs) yielded a TEP of –4.86 ± 0.32 
mV and SCC of 2.08 ± 0.27 µA, with a mean membrane resistance of 2.34 ± 
0.30 kilohms (KΩ) Fig 3.32. These values are similar to published values. 
Here, the Ussing chamber was circular in profile with a diameter of 3.5mm 
and therefore a surface area of 0.123 cm2. The mean baseline conductance 
per cm2 of the preparations was 3.47 m.siemens per cm2, which is similar to 
the value of 5 m.siemens per cm2 obtained by Ferguson (Ferguson et al. 
1997). The consistent baseline negativity of the transepithelial potential is 
indicative of an asymmetry of membrane ion transport between the luminal 
and basolateral surfaces of the urothelium. This could arise due to increased 
permeability to a cation such as Na+ at the luminal urothelial membrane (Fig 
3.41). Na+ permeability at the luminal layer is potentially under the control of 
P2X purinoreceptors.  
Figure 3.33 shows that there was a weak positive correlation between TEP 
and SCC. Figure 3.34 and 3.35 show the frequency distribution of TEP and 
SCC respectively indicating that both of these parameters have a positive 
skew distribution. The highest SCC and TEPs may have been associated with 
leaky membranes as a result of damage to the urothelium during the 
dissection process. 
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A range of experiments were carried out to ascertain the effect of purinergic 
and cholinergic agonists on the luminal and basolateral urothelium. The 
addition of ATP to the luminal urothelium resulted in increased negativity of 
the TEP, and increased SCC. This appears to be self-limiting as the effect 
was maximal at a concentration of 10-6 M, ∆TEP = -2.85 ± 0.15mV and ∆SCC 
= 0.4 ± 0.1µA (n=19, p<0.05) (Fig 3.36) and diminished at higher 
concentrations.  This may be due to luminal ATP having a complex effect on 
ionic transport. However, the addition of exogenous ATP to the basolateral 
urothelium did not have any effect on TEP or SCC and therefore flux of Na+ 
across the urothelium  (n=7) (Fig 3.37).  
 
Some preliminary experiments to assess the effect of a longer acting ATP 
analogue (ATPγS) on the apical urothelium were carried out. This was not 
found to have a significant effect, however the experiments were only carried 
out on two occasions and require further clarification (Fig 3.38). 
 
The addition of the non-specific cholinergic agonist carbachol at the basal (Fig 
3.39) and luminal epithelium (Fig 3.40) had no discernable effect on 
transepithelial potential or short circuit current.  
 
Ion flux that results in TEP 
We sought to clarify the ion that was being transported across the urothelium 
in response on the addition of exogenous ATP. 
The NaCl concentration at both the luminal and basolateral membranes was 
independently altered. The addition of 140mM NaCl (effectively doubling the 
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Na+ on one side) to the solution perfusing the basolateral urothelium resulted 
in a trend for increased negativity of TEP (∆TEP = 1.71 ± 1.02 mV, n =8) and 
increased SCC (∆SCC = 0.093 ± 0.069) (Fig 3.42). Addition of 140mM NaCl 
to the apical urothelium resulted in a reduction in negativity in TEP (∆TEP = 
2.65 ± 1.0 mV, p<0.05, n=20) (Fig 3.43). These results indicate that the 
baseline TEP is complex and dependent on the concentrations of several 
cations, and that Cl- may have an important influence as well. However these 
experiments were not carried out in iso-osmolar conditions, as increasing the 
NaCl concentration on one side of the urothelium increases the osmolarity on 
one side and this could influence the effect of transport of other ions. 
 
Combination of Purinergic agonists with ionic gradient 
We tested the addition of a combination of ATP 10-4 and 140mM NaCl to the 
luminal urothelium. Luminal ATP tends to increase the negativity of TEP but 
luminal NaCl decreases it. We found that under these circumstances the 
effect of NaCl predominated and TEP was increased (Figure 3.44 n=2, ∆ TEP 
= 0.49. The magnitude of this increase was less than that achieved by NaCl 
alone (∆TEP = 2.7 ± 0.9 mV from above and Fig 3.43). 
When combining the ATP analogue ATPγs with NaCl a trend for similar rise in 
TEP was noted (Figure 3.38), though statistical significance was not achieved. 
 
Isolating ionic flux
 
We have carried out further experiments to clarify the influence of either Na+ 
or Cl- on TEP. An iso-osmolar solution where NaCl was replaced by Na 
glucoronate was added independently to each half of the Ussing chamber 
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(this contained a reduced Cl- ion concentration of 9.6mM but a physiological 
concentration of Na+ of 140 mM). This experiment, which was carried out 
once, demonstrated that reducing the Cl- concentration on the luminal side 
resulted in an increased negativity of TEP (∆ TEP = -4.5mV and ∆SCC of 0.05 
µA). When reduced Cl- concentration was effected on the basolateral layer 
there was a corresponding slight increase in TEP (∆TEP =0.05mV). This 
experiment needs to be repeated but it indicates that Cl- flux from the 
basolateral to the luminal surface is an important determinant of TEP. The fact 
that altering the Cl- concentration on the luminal side had a greater effect may 
indicate that there is greater permeability for Cl- at the luminal side of the 
urothelium. 
 
By adding 140mM Na Pyruvate to the tyrodes solution perfusing the luminal 
half of the Ussing chamber, an attempt was made to increase the Na+ 
gradient without increasing the Cl- gradient (Fig 3.45). A trend for increased 
positivity of TEP was noted which was inconsistent with increased transport of 
Na+ from the luminal half of the Ussing chamber; perhaps indicating that 
pyruvate ion transport may have had a major effect on TEP in this experiment. 
This experiment unlike the Na-glucuronate experiment was not carried out 
under iso-osmolar conditions and the effect on the membrane conductance is 
similar to the addition of NaCl where the osmolarity was also effectively 
doubled on one side of the urothelium. 
 
The effect of nicotine 
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The addition of nicotine to either the basolateral (figure 3.46, n=3) or luminal 
half of the Ussing chamber (figure 3.47) had no discernable effect on TEP or 
SCC indicating that nicotinic receptors do not have an important effect on 
TEP. 
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Fig 3.31 Typical Ussing chamber trace; short circuit current (SCC) in red and 
transepithelial potential (TEP) in blue. Long arrows show the baseline reading 
of TEP (-ve) and SCC (+ve). Short arrows indicate the change in SCC (∆ 
SCC) and change in TEP (∆ TEP) in response to the addition of NaCl to the 
basal urothelium. 
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Fig 3.32 
 
 
 
Fig 3.33 
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Fig 3.34 
 
Fig 3.35 
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Fig 3.36 
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Fig 3.37 
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Fig 3.38 
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Fig 3.39 
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Fig 3.40 
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Fig 3.41 Proposed mechanism of action of ATP on the urothelium; luminal 
ATP release leading to depolarisation of the urothelium which spreads form 
the luminal to the basal surface, leading to ATP release from the basolateral 
surface and activation of afferent nerves. 
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Fig 3.42 
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Fig 3.43 
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Fig 3.44 
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Fig 3.45 
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Fig 3.46 
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Fig 3.47 
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Chapter 4 
 
Discussion
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4.1 Clinical impact of OAB 
Overactive bladder symptoms (OAB), defined by the International Continence 
Society as the presence of urinary urgency ± frequency ± nocturia ± urinary 
incontinence has a high prevalence, which is likely to increase in a population 
that continually achieves greater longevity. However, it is not a disorder that is 
restricted to the elderly and has an incidence approaching 10% in younger 
women (Irwin et al. 2006). OAB may cause considerable morbidity to its 
sufferers and place a strain on their working and social lives. Incontinence is 
associated with a multitude of other health problems in the elderly such as 
falls and depression (McGrother et al. 2006).  The burden that the 
management of incontinence places on the UK National Health Service is 
significant. The cost of nursing care and social services to manage the 
problem greatly exceeds the direct costs attributable to drug therapies. 
Improved symptomatic management with drug therapies have the potential to 
greatly reduce the indirect social costs attributable to urinary incontinence. 
 
A number of treatments are available for managing overactive bladder 
symptoms. The therapy that is initiated is dependent on symptom severity, the 
patient’s preferences and their functional status. Treatment is usually initiated 
in a stepwise fashion starting with the simplest and least invasive. Prior to 
commencing any drug treatment, the National Institute for Clinical Excellence 
(NICE) recommends bladder retraining and lifestyle measures such as 
reducing caffeine or alcohol intake. Bladder retraining aims to help patients 
who are complaining of urinary frequency and is achieved through the patient 
voiding at particular time intervals, which they may eventually lengthen until a 
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satisfactory gap between voids is achieved. Its effectiveness demonstrates 
that voiding is in part a behaviour that is under the influence of higher centres. 
Failure to respond to these measures will lead to the consideration of drug 
therapies. Antimuscarinic drugs are the mainstay of therapy of which there are 
several available. They differ slightly in their degree of muscarinic receptor 
subtype specificity (Appendix Table 1) and degree of tissue specificity for the 
bladder or other organs. The effect on other organs may lead to unwanted 
side effects such as dry mouth, constipation, blurred vision and cognitive 
impairment. As an example tolterodine has greater specificity for the M3 
receptor relative to the M2 receptor, determined by its pKB values, however 
oxybutynin is known to be more likely to cause dryness of the mouth (due to 
inhibition of M3 receptors within the salivary gland) than tolteridine as a result 
of increased tissue specificity for the salivary gland. There is no compelling 
evidence to recommend one anticholinergic over another (oxybutynin has 
shown marginally superior efficacy to tolteridine in a single RCT (Novara et al. 
2008)).  
 
The use of anitmuscarinics has revolutionised the treatment of OAB and 
spared many patients the need for bladder augmentation surgery. However 
not all patients are able to tolerate their side effects or attain a sustained or 
satisfactory response to treatment.  
 
For these patients, many clinicians would undertake urodynamics assessment 
to confirm the presence of detrusor overactivity characterised by the presence 
of involuntary detrusor contractions during the filling phase as a prelude to 
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further treatment. There is not always concordance between urodynamic 
findings and patients symptoms and the appropriateness of patient selection 
for botulinum toxin treatment on the basis of symptoms alone has been 
demonstrated (Ghei et al 2006). 
 
Botulinum toxin is utilised in patients with overactive bladder symptoms who 
have not responded to anticholinergics. It is administered locally into the 
bladder using a fine injecting needle at cystoscopy. The duration of action of 
botulinum toxin A is approximately 6-12 months. It has demonstrated an 
efficacy superior to that achievable by antimuscarinics alone (Ghei et al 2006) 
and its use has successfully been demonstrated in idiopathic and neuropathic 
detrusor activity and in interstitial cystitis and is likely to lead to further 
reductions in the number of patients requiring bladder augmentation surgery.  
 
Botulinum toxin is known to act through the inhibition of SNAP 25, a type of 
SNARE protein, which is essential for the exocytotic release of 
neurotransmitters. By analogy with its paralytic action on skeletal muscle it is 
assumed that its primary target is the detrusor muscle, however, its ability to 
inhibit neurotransmitter release from the urothelium and stop firing of the 
afferent sensory nerves is unevaluated. The superiority of botulinum toxin to 
antimuscarinic drugs in alleviating patient’s symptoms poses a number of 
physiological questions and presents a new benchmark for the 
pharmacological industry. Many patients will prefer oral medication to 
repeated cystoscopic injections and the question arises as to whether the 
same degree of efficacy can be attained with an oral medication.  
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To achieve this, firstly a much better understanding of the neurotransmitter 
signalling mechanisms of both the urothelium and the detrusor is required, 
particularly in the diseased state. The ideal oral drug or combination drug 
would have sufficient efficacy at the target receptor subtype(s) and sufficient 
tissue specificity to avoid unwanted side effects. 
 
There is some evidence of an associated change in neurotransmitter 
signalling both within the detrusor and within the urothelium. Atropine resistant 
contractions of the detrusor have been demonstrated in human and animal 
studies. There appears to be a smaller atropine resistant component in 
human tissue but it has been demonstrated that there is an increase in the 
atropine resistant component of nerve stimulated detrusor contractions with 
advancing age (Yoshida, Miyamae, Iwashita, Otani, & Inadome 2004). OAB 
symptoms increase with advancing age and atropine resistance or a change 
in neurotransmission from cholinergic to purinergic transmission is a plausible 
explanation for this. There is also evidence for a change of muscarinic 
receptor subtype. Detrusor contractions have largely been demonstrated to be 
mediated by the M3 receptor, which accounts for about 25% of the total 
population of muscarinic receptors within the detrusor. It has been 
demonstrated through the decreased effectiveness of darifenacin (M3 
selective inhibitor, appendix B) at inhibiting contractions that there is a 
tendency for reduced M3 signalling amongst patients with neuropathic 
overactivity relative to controls.  
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The urothelium is believed to be important as the primary relay of sensory 
signalling from the bladder via the afferent nerves. ATP has been 
demonstrated to be released from the bladder in response to bladder stretch 
and noxious stimuli. Increased urothelial ATP release has been found to be 
associated with interstitial cystitis (Sun et al. 2001) and UTI (Osterberg, 
Hallander, Kallner, Lundin, & Aberg 1991). Furthermore there is evidence for 
increased expression of urothelial P2X3 (Tempest et al. 2004) receptors 
amongst patients with interstitial cystitis. Inhibition of ATP transmission from 
the urothelium may be an important effect of botulinum toxin inhibition and 
therefore there is reason to believe that a selective ATP inhibitor may provide 
a useful therapy in OAB. 
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4.2 Comparison of organ bath experiments with isolated 
detrusor cell method. 
Organ bath experiments and isolated detrusor cell length measurements are 
two methods, which we have used to investigate the neurotransmitter 
regulation of muscle contractility. They are both assays of whole cell function 
and can provide only limited information about cellular mechanisms. Their 
utility is that they give a good corollary for in vivo drug efficacy and the use of 
these types of assays is likely to continue for the foreseeable future; given the 
large number of unknowns in intracellular function, it is not currently possible 
to construct a model of whole cell function based on the interactions of 
individual molecules. 
The organ bath experiments carried out here, perhaps offer a superior 
reproduction of in vivo conditions. Tissue preparation is relatively atraumatic 
and minimally disrupts cellular architecture. The matrix of muscle fibres is 
maintained and there is minimal cell death. By contrast, the process of 
isolating cells is likely to lead to the death of a fair proportion of the detrusor 
cells and the release of ions and neurotransmitters such as Ca2+ and ATP into 
the extracellular fluids. These have the potential to affect cell measurements. 
These effects were manifest in our experiments by the fact that even in 0 Ca2+ 
solution the addition of the Ca2+ channel blocker nicardipine led to an increase 
the resting cell lengths. The addition of suramin to the cell dispersal solution 
did not produce a further relaxation in myocyte lengths in the absence of the 
addition of any purinergic agonists, suggesting the presence of insignificant 
quantities of ATP in the cell dispersal solution. The organ bath experiments 
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were carried out under conditions of high O2 tension, controlled pH and 
temperature and constant perfusion. Constant bathing maintains the 
concentration of metabolites perfusing the tissue and washes away any by 
products of metabolism that may accumulate and have an inhibitory effect on 
contractility. It is possible that this methodological difference between these 
organ bath experiments and those of other authors may account for the 
observed difference in the effect of methoctramine on contractility. Whilst the 
isolated cell experiments were carried out under constant pH, temperature 
control and perfusion with O2 was not carried out. As the cells were 
suspended as a droplet on a slide there is very little barrier to diffusion of O2 
from room air into the suspension and into the isolated cells. 
 
Organ bath experiments uniquely allow for the assessment of the effect of 
endogenous neurotransmitters via the use of electrical field stimulation. By 
comparing the effect of an exogenous agonist and electrical responses it may 
be possible to draw some conclusions about presynaptic signalling. 
Acetylcholine analogues were used, as acetylcholine itself is unstable in 
solution. As exogenous acetylcholine analogues such as carbachol and 
oxotremorine are long acting due to their resistance to cleavage by 
acetylcholine esterase, their action on the postsynaptic membrane is likely to 
overwhelm any effect they may have on the release of endogenous 
neurotransmitters.  
An advantage of the isolated cell technique is that it allows confirmation that it 
is the detrusor cells themselves that are responding to cholinergic agonism, 
which is what we have observed. In a detrusor strip there are other cells such 
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as interstitial cells of cajal and neuronal cells. It is theoretically possible that 
an observed contraction could be due to an alternative neurotransmitter such 
as ATP being released by an intermediary cell in response to a cholinergic 
agonist and this diffusing to act on the detrusor cells. 
The isolated detrusor cells that are suspended in solution offer very little 
barrier to diffusion of an exogenous agonist and hence the observed EC50 for 
pharmacological agonists may be much lower than that achieved with much 
thicker detrusor strips and closer to the true working agonist concentrations 
within the neuromuscular junction.  
There are several other advantages of the isolated cell technique, principally 
that very small biopsy samples such as that obtained from flexible cystoscopic 
biopsies may be utilised which means that a much greater number of biopsies 
can be collected from a broader group of individuals, including controls. No 
controls were collected for the organ bath experiments, as biopsies were 
restricted to the subset of patients who were undergoing open bladder 
surgery. Unfortunately all of the patients who were undergoing cystectomy for 
bladder cancer were also describing overactive bladder symptoms, as were 
all of the patients undergoing clam cystoplasty be it of neuropathic or 
idiopathic origin; as would be expected of any individual requiring this surgical 
intervention. The ability to use flexible cystoscopic biopsies aditionally means 
that the research could be carried out in any laboratory affiliated to a district 
general hospital where flexible cystoscopic biopsies are routinely undertaken.  
The isolated detrusor experiments demonstrated remarkable statistical power 
as hundreds of cell lengths could be measured from a single biopsy sample 
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and therefore significant results could be obtained from a single biopsy 
sample.  
Utilising the isolated detrusor technique it is possible to measure changes in 
muscle cell plasticity. Changes in muscle length due to pathology are not 
detectable in organ bath experiments, as they may not alter the force 
generated per cross sectional area. 
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4.3 Organ bath experiments
 
The experiments on human detrusor muscle strips provide evidence of 
significant M2 receptor signalling in human detrusor from patients complaining 
of both neuropathic overactivity and OAB. This was manifest by 10 nM 
methoctramine producing sizeable inhibition of contractions induced by 
carbachol, oxotremorine and electrical field stimulation. 10nM is compatible 
with M2 rather than M3-dependent inhibition (Appendix, Table 1). This is the 
first time that M2 activity has been demonstrated in patients with detrusor 
overactivity and the first time that evidence for M2 activity has been 
demonstrated directly in human tissue using an M2 inhibitor. It is not possible 
to use an M2 agonist, as no such selective ligand is available. M2 activity in 
human detrusor has previously been inferred from the relative ineffectiveness 
of darifenacin, a selective M3 ligand in inhibiting muscarinic agonists amongst 
patients with neuropathic detrusor overactivity (Pontari, Braverman, & 
Ruggieri, Sr. 2004). We do not know why M2 activity has not been 
demonstrated previously when an M2 inhibitor was used to inhibit detrusor 
contractions in the human bladder. It is possible that this is due to 
methodological differences. Firstly, these experiments were carried out with a 
30-minute washout period in-between agonist exposure rather than a 
cumulative dose response carried out without a washout. We have 
demonstrated that this does not desensitise the agonist responses during the 
experimental period. Secondly all experiments were carried out under 
continuous perfusion. This has the benefit of removing any products of 
metabolism, which may accrue in the tissues and have a deleterious affect on 
function. The disadvantage of this technique is that it is much more time 
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consuming and fewer pharmacological interventions can be applied within a 
given experimental time frame. 
 
Significant M2 activity was present in all the patients studied. All twelve 
patients had overactive bladder symptoms, albeit from different aetiologies. 
They were undergoing open bladder surgery so were not representative of the 
general population but may be representative of many symptomatic patients 
who may benefit from treatment with anticholinergic drugs.  
The study is limited by two factors; firstly the overall patient numbers and the 
lack of control patients. Previous experience of human tissue strip work within 
the laboratory indicate an average of 45% difference between mean sample 
variables, x1-x2, (where x1 and x2 denote the mean of two distinct samples 
groups) with sample standard deviations about 40% of the value. For a 
significant difference at p ≤0.05 , the standardised normal deviate, u0.05 =1.96. 
The desired sample number, n, is n>2(u0.05.s/x1-x2)2 =6.1, which can be 
rounded up to 7. Whilst there was the potential to collect full thickness 
biopsies  from patients who were undergoing cystecomies; all of these 
patients were symptomatic when questioned. As there was also no 
discernable difference demographically or experimentally between the two 
groups, the overactive and neuropathic overactive patient groups were pooled 
together and thus analysis was of a single larger heterogenous group who all 
complained of OAB symptoms regardless of the aetiology. This is not ideal, as 
it does not allow investigation of the pathological differences between the two 
groups, but within this data set it has allowed for unequivocal documentation 
of M2 activity (which is a noteworthy finding) by increasing the sample size 
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above the desired level. However, we cannot answer the question of whether 
M2 activity would have been found in controls using our experimental protocol. 
Furthermore the summary table on page 81 shows that not every experiment 
was carried out on every patient and some experiments were carried out 
fewer than 7 times. The patient numbers allow for demonstration of agonist 
efficacy and M2 activity but there are not sufficient numbers to distinguish 
between the OAB and neuropathic OAB groups let alone controls. 
 
This is only the second study to collect detrusor biopsies from patients who 
are documented to have overactive bladder symptoms not due to a 
neuropathic aetiology (Stevens, Chapple, & Chess-Williams 2007). The 
findings here contrast with that study in that no evidence of M2 activity was 
found in their study amongst any of the patient groups, be they control 
patients (undergoing cystectomy for cancer), OAB patients or neuropathic 
overactive patients, as methoctramine only inhibited carbachol contractions 
when it was used in the micromolar range in muscle strips from all of the 
patient groups. This is consistent with its inhibition of the M3 receptors at 
higher concentrations. The reason for the differences in findings between the 
two studies remains uncertain, however it may be due to the differing 
methodologies used, as discussed above.  
 
We however, have found that OAB patients like the neuropathic patients have 
significant M2 activity. Our results support Pontari’s findings that there is 
significant M2 activity amongst neuropathic patients. Since it was not possible 
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to study normal controls here, the pathological deviation from normality 
cannot be accounted for in this study.  
 
Methoctramine (10 nM) produced significant inhibition of EFS responses in 
addition to agonist-induced responses. EFS is both more physiological and 
complex, resulting in the release of not just acetylcholine but other 
neurotransmitters (Bayliss, Wu, Newgreen, Mundy, & Fry 1999). 
Methoctramine could potentially have a dual action on EFS, by facilitating pre-
synaptic acetylcholine release and inhibiting its post-synaptic actions, as there 
are believed to be inhibitory prejunctional M2 receptors (Braverman et al. 
1998). However no evidence of this effect was witnessed here, as the 
magnitude of EFS inhibition was similar to that induced by agonists. As an 
example, 10nM methoctramine reduced contractions elicited by 1µM 
oxotremorine (pEC50=6.1) by 48% (from Fig 3.2a) and contraction elicited by 
16Hz EFS by 39% (from Fig 3.7b).  
Although oxotremorine is often described as a non selective agonist, Griffin in 
his study of the recombinant human M2 and M3 receptor in Chinese hamster 
ovary cells demonstrated that oxotremorine had a pEC50 of 7.44 for inhibition 
of cAMP accumulation (an M2 effect) and pEC50 of 6.23 for phosphoinosotide 
hydrolysis (an M3 effect) (Griffin et al. 2003). A stronger association between 
agonist pEC50 of oxotremorine and the pKB of methoctramine against 
oxotremorine has been demonstrated. This means that patients with detrusor 
strips that were more sensitive to oxotremorine could also be inhibited to a 
greater degree by methoctramine i.e. had greater M2 activity. This would be 
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compatible with M2 receptor signalling increasing the sensitivity of the 
detrusor to acetylcholine 
An age-associated reduction in the potency of oxotremorine, but not of 
carbachol, and reduction in maximal EFS response relative to an agonist was 
recorded. Diminished EFS responses would be compatible with a reduction in 
nerve function with advancing age. Nonetheless, these findings accord with 
previous studies which have described decreased cholinergic and increased 
purinergic activity in older persons (Yoshida, Miyamae, Iwashita, Otani, & 
Inadome 2004). However the dataset accumulated here is clearly much 
smaller and caution needs to be exercised in interpreting the age related 
trends. 
 
Anticholinergic medications are the most common treatment employed for 
patients with overactive and neuropathic overactive bladders. The data 
suggest that M2 receptor blockade may be beneficial.  M3 targeting amongst 
the latest generation of anticholinergics such as darifenacin and solifenacin, is 
frequently cited, without evidence, for offering therapeutic advantage. 
However the present study suggests otherwise. Avoiding inhibition of cardiac 
M2 receptors, however, may be desirable, although the most common side 
effect causing discontinuation of these drugs is dryness of the mouth, an M3 
effect. 
 
Activated M2 and M3 receptors preferentially couple to different G proteins, M3 
to Gq/11 and M2 receptors to Gi/o. One potential mode of action of M2 
activation is Gi/o-mediated inhibition of adenylyl cyclase and reduction of 
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cAMP levels (Somlyo & Somlyo 2003). This could increase force by 
increasing myosin light chain phosphorylation either by protein kinase A 
inhibition or rho kinase activation (Zholos & Bolton 1997) or facilitation of 
extracellular calcium entry (Eglen & Watson 1996). Our experiment 
encourages further scrutiny of these mechanisms. 
 
In conclusion we believe that the M2 receptor plays a significant role in 
modulating contractions in the overactive human detrusor. 
 
We have demonstrated significant M2 activity in guinea pig detrusor 
contractions.  However, this could only be demonstrated when oxotremorine 
rather than carbachol was used as an agonist. Oxotremorine and carbachol 
are both full agonists however oxotremorine is significantly more potent. The 
potency of oxotremorine in the presence of methoctramine is similar to that of 
carbachol, which is unaffected by any of the M2 acetylcholine inhibitors used 
here.  Forskolin had a similar effect to methoctramine, i.e. no effect on 
carbachol contractions and inhibition of oxotremorine to the same degree as 
that obtained by 10nM methoctramine. It is tempting to conclude that in this 
preparation, oxotremorine is producing Gi0 mediated inhibition of adenylate 
cyclase whereas carbachol does not. Previous studies examining the effect of 
recombinant porcine M2 receptor activation have found no inherit difference 
between the activatory function of carbachol and oxotremorine (Vogel, 
Sheehan, & Schimerlik 1997), as both agonists are capable of inducing IP3 
activation and adenylate cyclase inhibition albeit at different concentrations; 
carbachol favouring IP3 production and oxotremorine favouring adenylate 
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cyclase inhibition. Though we can find no equivalent study in guinea pig 
detrusor.  
However, the experiments with oxotremorine demonstrate that forskolin and 
methoctromine have equivalent effects and that inhibition of cAMP is an 
important step in M2 signalling that has a significant modulatory effect on 
detrusor contractility. This equivalence of action is illustrated below. Forskolin 
has previously been demonstrated to reduce the frequency of spontaneous 
action potentials in guinea pig detrusor in a Ca2+ independent manner 
however this has not been previously been shown to be mediated by the M2 
receptor (Hashitani et al. 2004). 
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Parallel shift in dose response was not attained when methoctramine was 
used to inhibit oxotremorine dose responses in guinea pig detrusor and thus 
the pKB of methoctramine was calculated utilizing the shortened version of the 
schild equation. A simple competitive binding model thus cannot explain the 
observed inhibition of oxotremorine-mediated contractions by methoctramine 
in the guinea pig detrusor. Possible explanations include the unknown 
additive effect of simultaneous M2 and M3 receptor activation, oxotremorine 
and methoctramine acting on a high affinity binding site which carbachol does 
not activate or the differential effect of carbachol and oxotrmorine on M2 and 
M3 hetero and mono dimers. 
Methoctramine produced inhibition of EFS at concentrations of 100nM and 
above but not at 10nM where as 4DAMP produced inhibition at 3nM and 
above. These results are inconclusive in terms of determining the proportional 
effect of M2 and M3 receptor activation as at these concentration 4DAMP and 
methoctramine will each be inhibiting M2 and M3 receptors. It is likely that both 
receptor populations contribute to contraction with the M3 receptor 
predominating. 
In these experiments, M2 activation was much easier to demonstrate in 
human detrusor (albeit pathological) than in the guinea pig. Nonetheless M2 
signalling contributes directly to detrusor contraction in both tissues.  
 
These experiments also indicate that caution should be exercised in 
extrapolating results from animal models to humans particularly when only 
one acetylcholine analogue is used in experimentation. We like some 
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previous authors have failed to demonstrate M2 acetylcholine activity in the 
(guinea pig) detrusor when carbachol alone was used as an agonist (Chess-
Williams et al. 2001). 
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4.4
 
Isolated detrusor cells 
In 1979 a technique was used to assess smooth muscle contractility which 
involved the dispersion of individual viable cells from a small sample of 
stomach tissue (Bitar, Zfass, & Makhlouf 1979). Isolated gastric smooth 
muscle cells were prepared from the stomach of Bufo marinus by successive 
incubation in collagenase without added trypsin.  
Since this time, the approach has been applied to various tissues, particularly 
the gastrointestinal tract, from a number of mammalian species, including 
humans (Bitar & Makhlouf 1982). These preparations have been used to 
study the mechanical and biomechanical properties of the cells (Seidel & 
Johnson 1983; Collins & Gardner 1982).  
 
The isolated detrusor experiments conducted here based on Bitar’s method 
represent the first time that this technique has been used on human detrusor 
tissue. As detailed previously, there are few studies investigating detruosr 
contractility in human tissue and most conclusions have been drawn from 
animal studies. The great potential for this technique is that detruosr 
contractility can be measured using tiny biopsy samples that can be obtained 
from cystoscopies rather than the full thickness bladder biopsies which are 
required from organ bath experiments that can only be obtained from open 
bladder surgery such as cystectomy and clam ileo-cystoplasty. This provides 
the opportunity for many more samples to be collected from a greater number 
of patients who may be better representative of patients with lower urinary 
tract symptoms.  
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The method proved successful in producing a large yield of viable detrusor 
cells for the purpose of pharmacological probing. A small biopsy weighing 0.1 
g could yield > 10000 cells of which 70-80% were alive as determined by 
trypan blue staining. 
Furthermore, through counting a large number of cell lengths from a single 
sample, statistically significant results could be obtained on each sample 
though each experiment was repeated at least 3 times in order to obtain a 
mean of means.  
A comparison between the three species studied; human, rat and guinea pig 
reveal similar resting cell lengths of 80-100µm. Resting cell lengths were 
normally distributed.  A good range of contractility could be demonstrated with 
an almost 50% reduction in cell length brought about by the addition of 100µM 
carbachol, when compared with the maximally relaxed state in the presence 
of zero Ca2+ and the Ca2+ channel antagonist nicardipine. Addition of Ca2+ 
ions produced an incremental shortening of detrusor cell lengths with the near 
plateau effect achieved at 0.5mM.  Somewhat surprisingly cells were 
significantly more relaxed when nicardipine was added to a zero calcium 
solution. There are several possible explanations for this; firstly that there is 
release of intracellular calcium into the extracellular space as result of 
equilibration of ionic concentrations across the cell membrane, secondly that 
there is increased calcium release due to break down of cell membranes 
brought about by the cell separation process, and thirdly there may have been 
a small concentration of Ca2+ contaminating the Tyrodes solution. This 
possibility may have been excluded through the addition of the Ca2+ chelator 
EDTA to the cell suspension solution. Cell membrane breakdown may lead to 
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the release of other neurotransmitters such as ATP. To explore this possibility 
the non-selective purinergic antagonist suramin was added to the cell 
dispersal solution, however this did not produce a further relaxation of the 
cells when used alone or in conjunction with nicardipine.  
It was aimed to get the cells in a state of maximal relaxation prior to the 
addition of any of any contracting agent without inhibiting their contractility so 
that the greatest change of length could be produced and therefore the 
highest signal relative to noise. Nicardipine and zero calcium solutions were 
clearly able to relax the cells, however both of these conditions would inhibit 
contractility and therefore agonist reactions were carried out in 0.5mM Ca2+ 
and the absence of nicardipine. As suramin had no relaxatory effect it was 
elected not to use this to relax the cells simultaneously with agonist addition.  
 
The maximal effect of the agonists carbachol and oxotremorine on isolated 
detrusor cell contractions were comparable just as the case with the organ 
bath experiments. 
 
The values of EC50 for agonist response with carbachol and oxotremorine 
utilising the dispersed cell method are comparable to that obtained by the 
organ bath experiments indicating that the diffusional barrier to exogenous 
agonists activating muscarinic receptors on the detrusor muscle, may have 
not been a factor in the organ bath experiments.  
 
The time series experiments carried out here, indicate that rat detrusor 
myocytes contract faster than human detrusor myocytes, reaching peak 
 160
shortening within 30 seconds and after 45 seconds, there is diminished 
agonist induced shortening thereafter, indicating receptor desensitisation. 
 
Some M2 activity was demonstrated in the rat detrusor on the single occasion 
when methoctramine was used against carbachol, however parallel shift was 
not achieved. An estimated pKB of 9.23 was obtained. The analogous organ 
bath experiment was not carried out in rat detrusor. In the case of guinea pig 
detrusor M2 inhibition could not be detected when methoctramine was used 
against carbachol but only when methoctramine was used against 
oxotremorine. M2 activity was demonstrated in organ bath experiments 
involving human detrusor where methoctramine was used against carbachol. 
In this case an experimental pKB achieved which was higher than the values 
achieved in human organ bath experiments. 
 
Using the single cell dispersal technique we can assess cell lengths from 
different patient groups. Surprisingly, this has never been done before. Other 
groups have looked at changes in muscle cell diameter but not length, as the 
single cell dispersal technique has not been used before on human detrusor 
tissue for the purpose of measuring cell length. In a histological section 
through a muscle biopsy, the orientation of the muscle cells is random and 
there is greater likelihood by chance of obtaining transverse sections across 
muscle cells, as they are long and thin. It has been shown that in patients with 
bladder outflow obstruction, that muscle cells hypertrophy and become thicker 
(Uvelius, Persson, & Mattiasson 1984). However we do know that bladder 
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adaptation can lead to changes in bladder capacity and the single cell 
technique allows us to measure cell length and diameter 
Outflow obstruction in men due to prostatic enlargement is a slow process, 
which occurs over many years resulting in changes to bladder function. 
Initially, outflow obstruction may result in voiding with increased pressures, as 
the bladder must do more work to overcome the resistance. This can lead to 
overactive symptoms, similar to those experienced by patients with idiopathic 
overactivity. With time the bladder gradually enlarges in some men and it is 
not unusual to see patients with prostatic enlargements having bladders of 1 –
2 litres capacity. This is much more than the normal male bladder capacity of 
500- 600ml. Enlargement of the bladder could arise in one of three ways; 
either by the muscle cells becoming longer or by the cells becoming interlaced 
with fibrous tissue and thus becoming more spread out (Gosling & Dixon 
1980;Inui et al. 1999) or by an increase in cell numbers (de Castro Sasahara 
et al. 2007; Nielsen et al. 1995). Furthermore patients with long standing 
chronic retention tend to void at lower bladder pressures and are said to have 
atonic bladders.  Laplace’s law describes the relationship between wall 
tension and pressure in a spherical elastic container and predicts that the 
pressure of the liquid is proportional to the wall tension but inversely 
proportional to the radius. Therefore an atonic bladder may produce lower 
pressures simply because it is larger and not because there is any reduction 
in contractile force of the muscle.  Three hypotheses that were tested were:  
1) Patients with outflow obstruction have longer bladder cells.  
2) Muscle cells from patients with outflow obstruction undergo the same 
percentage shortening as control and overactive patients.  
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3) Detrusor cells from OAB patients undergo a lower percentage lengthening 
when an agonist (muscarinic and purinergic) is added as the cells are already 
partially contracted in their resting state. 
All of the above comparisons were affected by describing a working muscle 
range for each patient group. A resting length was measured by adding a 
physiological concentration of Ca2+ and nothing else to cells on one slide; the 
aim was to represent the muscle length during the storage phase when the 
efferent nerves to the detrusor are quiescent and the detrusor muscle is 
exposed to low concentrations of endogenous agonists. A fully contracted 
length was achieved by adding a high dose of non selective muscarinic 
agonist carbachol to another slide and a fully relaxed length could be 
assessed by adding a high concentration of antagonists, both muscarinic 
(atropine) and purinergic (suramin) to cells on another slide.  
The antagonists might have been expected to have an effect because within 
the cell dispersal solution, the endogenous neurotransmitters acetylcholine 
and ATP will be present.  Some of this may be due to physiological release 
but a significant proportion will be due to cell disruption as a result of the 
dispersal process.  Furthermore, it is possible that an antagonist can have a 
direct effect on a receptor if it has inverse antagonistic function. About 85% of 
antagonists are estimated to promote inverse antagonism (Kenakin 2001) 
The data in figure 4.30, would support hypothesis 1 and 2 . The nine patients 
with OAB and the nine control patient would appear to demonstrate a resting 
length which is closer to a contracted length that was achieved with 100 µM 
carbachol. However as detrusor muscle in OAB has shown to exhibit 
increased atropine resistance then these muscle cells need to be contracted 
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with ATP as well to see if they can be further shortened. These data 
demonstrates for the first time that detrusor cells can elongate in response to 
outflow obstruction. Clearly this finding needs to be corroborated in a large 
group of patients, relating detrusor cell length to residual volume and bladder 
capacity.  
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4.5 The urothelium  
In summary ATP when released from the luminal surface of the urothelium 
may result in a P2X mediated flux of cations from the urine into the 
urothelium, which is manifest by increased SCC and increased TEP. 
However, this mechanism appeared to be self-limiting because higher ATP 
concentrations reverse this effect. No ionic flux was noted when ATP was 
added to the basolateral surface or when cholinergic or nicotinic agonists 
were added to either surface.  The luminal purinergic response reflects an 
asymmetry in the distribution of P2X receptors across the urothelium.  
The effect of altering NaCl concentration indicates that the baseline TEP is 
not simple and is dependent on the concentrations of several cations and that 
Cl- fluxes have an important influence. 
 
 Measurement of baseline electrical properties; the baseline transepithelial 
potential (TEP), short circuit current (SCC) and conductance were made. 
Baseline measurements (Figure 3.32, n = 56 guinea pigs) yielded a TEP of -
4.86 ± 0.32 mV and SCC of 2.08 ± 0.27 µA with a mean membrane resistance 
of 2.34 ± 0.30 Kiliohms (kΩ). The consistent baseline negativity of the 
transepithelial potential is indicative of an asymmetry of membrane ion 
transport between the luminal and basolateral surfaces of the urothelium. This 
could arise due to increased permeability to a cation such as Na+ at the 
luminal urothelial membrane. Na+ permeability at the luminal layer is 
potentially under the control of P2X purinoreceptors. 
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A range of experiments was carried out to ascertain the effect of purinergic 
and cholinergic agonists on the luminal and basolateral urothelium. We 
originally hypothesised that exogenous ATP would principally act at the 
basolateral urothelium and allow the efflux of positive ions. However we were 
unable to demonstrate that the addition of exogenous ATP to the basolateral 
urothelium had an effect on TEP or SCC and therefore flux of Na+ across the 
urothelium  (Figure 3.36, n=7). However, the addition of ATP to the luminal 
urothelium resulted in increased negativity of the TEP, and increased SCC. 
The effect appears to be self-limiting as the response was maximal at a 
concentration of 10-6 M, ∆TEP = -2.85 ± 0.15mV and ∆ SCC = 0.4 ± 0.1µA 
(Figure 3.37 n=19, p<0.05), and diminished at higher concentrations.  This 
may be due to luminal ATP having a complex effect on ionic transport, 
perhaps having different effects on different classes of purinergic receptors. 
We carried out some pilot experiments to assess the effect of an ATP 
analogue ATPγS on the urothelium. This was not found to have a significant 
effect however the experiments were only repeated on two occasions and 
needs further clarification. 
 
The addition of non-specific cholinergic agonist carbachol at the basal and 
luminal epithelium (Figure 3.39 and 3.40) had no discernable effect on 
transepithelial potential or short circuit current. Likewise the addition of 
nicotine (Figure 3.36 and Figure 3.47) had no discernable effect on TEP and 
SCC. The lack of action of muscarinic agonists indicates ionic flux is governed 
by a mechanism independent of acetylcholine /muscarinic receptors. This is 
not to say that muscarinic signalling does not have a role in conveying a 
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sensory signalling just that it may not alter urothelial cell transmembrane 
voltage and therefore could not be detected by this assay. The lack of action 
of nicotine suggests that nicotinic receptors do not play an important role in 
urothelial function, as activation of nicotinic receptors leads to opening of an 
ion channel and this effect is likely to lead to an appreciable change in TEP 
and SCC  which was not detected here. 
The effect of luminal ATP and lack of effect of basolateral ATP on the 
urothelium is of interest and has caused us to proffer an alternative model of 
how we believe the urothelium is functioning as a microsensor relaying 
sensory signals to the afferent nerves located in close proximity (Figure 3.41). 
ATP has been shown to be independently released from both surfaces of the 
urothelium (Lewis & Lewis 2006) and therefore both of these effects need to 
be addressed. These experiments suggest that basal ATP release may not 
have an important feedback function on the urothelium and may primarily 
function as a direct feed forward on to afferent nerves and suburothelial cells. 
However the role of luminal ATP release has never been addressed before 
and therefore the question arises as to what is the purpose of release of ATP 
from the luminal urothelium into the urine when the sensory nerves are 
located on the other side. The experiments here suggest that luminal ATP 
release acts as feed forward, working directly on the urothelium so as to 
increase the flux of cation form the urine into the urothelium. We have 
interpreted this as a sensory mechanism. The urothelium is a thick epithelial 
surface of about 5 – 7 cells deep and this mechanism may be a means of 
conveying a sensory signal such as bladder stretch or inflammation which 
primarily occurs at the luminal side of the urothelium, from the luminal to the 
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basal side by causing a depolarisation of the urothelium which starts at the 
luminal surface and spreads to the basal surface.  This could lead to release 
of ATP and other neurotransmitters from the basolateral layer of the 
urothelium that may act on the sensory nerves and propagate this sensory 
signal. We believe this model offers a logical explanation of urothelial 
electrical properties, as firstly ATP is controlling Na+ flux on the same side that 
it is acting and signal transduction proceeds sequentially from inflammatory 
signal (urinary side) to the afferent sensory nerves on the basolateral surface. 
We have not clarified the purinergic receptor that is mediating the ionic flux 
but we believe that activation of P2X receptors which control Na+ current is a 
likely candidate. The P2X3 receptor expression has been found to be 
increased in interstitial cystitis which is an inflammatory disorder characterised 
by symptoms of urinary urgency, frequency and pain (Sun & Chai 2004). 
The increased presence of ATP has been found in the patients suffering with 
inflammatory conditions such as UTI (Osterberg et al. 1991) and interstitial 
cystitis (Caulfield 1993). It is possible that symptoms may be mediated by 
excessive signalling form the urothelium and therefore there exists the 
potential for effecting a treatment through the use of specific purinergic 
inhibitors. The lack of effect of muscarinic agonists does not necessarily mean 
that acetylcholine has no important effect on the urothelium merely that an 
effect could not be detected by this functional assay and therefore ion flux or 
membrane depolarisation may not be part of its mode of action. The lack of 
action of nicotine suggests that nicotinic receptors do not play an important 
role in urothelial function, as activation of nicotinic receptors leads to opening 
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of an ion channel and this effect is likely to lead to an appreciable change in 
TEP and SCC. 
 
Ion flux that results in TEP 
We sought to clarify the ion that is being transported across the urothelium in 
response on the addition of exogenous ATP. 
We altered the NaCl concentration on both the luminal and basolateral 
membranes. Addition of 140mM NaCl (effectively doubling the Na+ on one 
side) to the perfusing solution to the apical urothelium resulted in a reduction 
in negativity in TEP (∆TEP = 2.65 ± 1.0 mV, p<0.05, n=20) (Fig 3.43) and 
addition of 140mM to the basolateral urothelium resulted in a trend for 
increased negativity of TEP (∆TEP = 1.71 ± 1.02 mV, n =8) and increased 
SCC ( ∆SCC = 0.093 ± 0.069) (Fig 3.42). These results indicate that the 
baseline TEP is complex and dependent on the concentrations of several 
cations, and that Cl- have an important influence as well.  
Further experiments to clarify the influence of either Na+ or Cl- on TEP were 
carried out. An iso-osmolar solution where NaCl was replaced by Na-
glucoronate was added independently to each half of the ussing chamber (this 
contained a reduced Cl- ion concentration of 9.6mM but a physiological 
concentration of Na+ of 140 mM). This experiment was carried out once but it 
demonstrated that reducing the Cl- concentration on the luminal side resulted 
in an increased negativity of TEP (∆ TEP = -4.5mV and ∆SCC of 0.05 µA). 
When reduced Cl- concentration was effected on the basolateral layer there 
was a corresponding slight increase in TEP (∆TEP =0.05mV). This 
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experiment needs to be repeated but it indicates that Cl- flux from the 
basolateral layer to the luminal is an important determinant of TEP. 
 
 
Concluding message 
These data support the hypothesis that luminal release of ATP results in 
depolarisation of the urothelium starting from the luminal surface and 
spreading to the basolateral surface, potentially leading to increased 
neurotransmitter release from the basolateral surface.  We believe that this 
constitutes a mechanism whereby a sensory signal, such as that generated 
by inflammation of the luminal urothelium, can be conveyed to the basolateral 
urothelium where sensory nerves are in proximity. The experiments regarding 
the ionic flux, which is contributing to TEP do provide some insight. The 
results suggest that it is complex and more than one ion contributes and in 
particular the permeability of Cl- is important. The next steps are to identify of 
the purinergic receptor subtype(s) that are mediating the ATP induced change 
in TEP. There is potential that identification will lead to novel treatments for 
patients suffering with overactive bladder symptoms. 
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Future Plan of Investigations 
Detrusor 
The experiments here highlight a role for M2 receptors in the direct modulation 
of detrusor contractility. This study demonstrates M2 activity using M2 
preferential inhibitors – methoctramine and gallamine. This the most direct 
means possible of demonstrating M2 activity as there are no muscarinic 
agonists with sufficient specificity for the M2 over and above the M3 receptor 
Clearly there is much to be elucidated in clarifying its mechanism of action of 
the M2  receptor. The experiments with forskolin suggest that adenyly cyclase 
inhibition and reduction of cAMP concentrations is an important function of M2 
activation that is capable of increasing the force of contraction in a Ca2+ 
independent manner. These experiments were only carried out on guinea pig 
detrusor and it would be worth carrying out these experiments on a range of 
human tissues particularly as M2 activity was easier to demonstrate in human 
detrusor preparations.  
 
Isolated detrusor cell experiments 
The isolated detrusor cells experiments have demonstrated the potential of 
using small cystoscopic samples to assess detrusor contractility and plasticity 
in diseased states. There are a huge range of experiments yet to be done, 
from clarifying the role of cAMP inhibition mentioned above to clarifying the 
role that ATP has in mediating detrusor contraction and using specific ATP 
inhibitors such as TNP ATP and RB2 to identify the purinergic subtype 
mediating contractility where atropine resistant contractions occur. 
 172
The hypothesis that detrusor cells from atonic bladders maintain contractility 
and failure to void may largely be due to the failure of a large bladder to 
generate pressure needs to be further explored. To demonstrate this 
hypothesis detrusor samples need to be taken from patients with chronic 
obstruction and larger bladder volumes of 1-4 litres. This work could be 
continued in an experimental animal model whereby bladder hypertrophy and 
urinary retention is induced in animals by occluding the urethra. An attempt at 
restoring voiding function in such animals could be made through excising,  
tying off, or stapling off part of the bladder so as to reduce bladder volume. If 
detrusor cells in these animals still have good contractile function then voiding 
function could be restored. If this were the case then the ramifications for 
many patients would be quite profound, as the changes in bladder function 
due to outflow obstruction have so far been demonstrated to be largely 
irreversible. However if the only change is one of size rather contractility then 
this could be reversed by a surgical reduction of the bladder. Currently 
patients who have developed chronic retention due to outflow obstruction may 
not be able to void even after the obstruction in the outflow tract is surgically 
relieved and therefore require lifelong indwelling or intermittent self 
catheterisation in order to void. 
Furthermore, the mechanism of detruosr hypertrophy could be explored. It 
has been largely assumed that bladder hypertrophy results passively in 
response to pressure, however it is plausible too that there are physiological 
control mechanisms. As previously documented here the bladder releases a 
host of neuropeptides such as ATP and acetylcholine when it is stretched. It is 
possible that that these are growth as well as sensory signals and that 
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inhibiting these neurotransmitters through the use of cholinergic and 
purinergic inhibitors could reduce the rate of bladder hypertrophy. 
Furthermore some patients with OAB and neuropathic bladders have low 
capacity, poor compliance and elevated pressures. An alternative to bladder 
augmentation surgery for these patients could be induction of bladder muscle 
elongation if the growth signals are elucidated. 
 
 
Urothelium 
 
Although ATP was demonstrated to have an effect when it was added to the 
luminal half of the Ussing chamber we need to clarify the effect of ATP on the 
luminal and basal urothelium at low concentration and clarify the receptor 
subtype that is mediating contraction using ATP inhibitors such as suramin 
ppads, TNP ATP, RB2. It would be also be instructive to attempt to block 
apical Na channels by adding luminal amiloride as this would support our 
hypothesis. The experiments with ATPyS and ATPyS combined with NaCl 
need to be repeated to determine if the same effect as that produced by ATP 
is yielded as would have been expected. 
 
It would be desirable to clarify ion transport generating TEP. To achieve this, 
Cl- and Na+ replacement solutions of fixed osmolarity using a non- 
transported anion and cation respectively need to be added to each side of 
the urothelium. Chloride ion transport could be further elucidated through the 
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use of Cl- channel blockers, e.g. - indanyloxyacetic acid (IAA-94) or 4,4'-
diisothiocyanatostilbene-2,2'-disulphonic acid (DIDS). 
 
The relationship between TRPV channels and transepithelial potential could 
be explored through the addition of capsaicin or resinferatoxin to the luminal 
urothelium, to inhibit TRPV channels and determine whether these are 
involved in ATP release. 
 
 
We would like to further test the hypothesis that luminal ATP release result in 
basolateral release after the urothelium becomes depolarised by; 1) 
Measuring ATP in the effluent in each half of the ussing chamber in response 
to the addition of ABMA on each side. If this is true that basal ATP release is 
stimulated most by the addition of luminal ABMA. 2) Demonstrating that 
Urothelium is impermeable to ATP through the addition of radiolabled ATP to 
each half of ussing chamber and testing the effluent in each half for the 
presence of the radiolabelled ATP. 
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Table 1 Muscarinic Antagonists and their specific pKB values for each 
receptor 
 
  
(Caulfield 1993),(Hou, Hirshman, & Emala 1998),(Eglen & Watson 1996) 
  
Antagonist 
 
  
M1 
 
  
M2 
 
  
M3 
 
  
M4 
 
  
M5 
 
atropine 
 
9.0 – 9.7 
 
9.0 – 9.3 
 
8.9 – 9.8 
 
9.1 – 9.6 
 
8.9 – 9.7
 
pirenzipine 
 
7.8 – 8.5 
 
6.3 – 6.7 
 
6.7 – 7.1 
 
7.1 – 8.1 
 
6.2 – 7.1
 
4 DAMP 
 
8.6 – 9.2 
 
7.8 – 8.4 
 
8.9 – 9.3 
 
8.4 – 9.4 
 
8.9 – 9.0
 
Methoctramine 
 
7.1 – 7.8 
 
7.8 – 8.3 
 
6.3 – 6.9 
 
7.4 – 8.1 
 
6.9 – 7.2
 
Gallamine 
 
  
 
6.2 
 
4.5 
 
  
 
  
 
Oxybutynin 
 
8.5 
 
7.8 
 
8.7 
 
8.2 
 
7.6 
 
Tolteridine 
  
 
8.5 
 
8.4 
 
8.5 
 
8.1 
 
8.6 
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Table 2 Purinergic receptors, summary of distribution, agonists and 
antagonists (Burnstock 2007). 
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Figure 5 The role of calcium in mediating detrusor contractions. 
 
Major signal transduction pathways that modulate myocyte tone.
       
(+) denotes a positive or stimulatory effect; (–) denotes a negative or inhibitory 
effect. M2 and M3- muscarinic receptors. BKCa, the calcium-sensitive K 
channel (maxi-K), although clearly there are several types of K channels 
known to be present in detrusor myocytes; SR, sarcoplasmic reticulum; RyR, 
ryanodine receptor; PLC, phospholiapse C; DAG, diacylglycerol; PKA, protein 
kinase A; IP3, inositol trisphosphate; MLC, myosin light chain; A, agonist; R, 
receptor; CPI-17, protein kinase C-potentiated protein phosphatase-1 
inhibitory protein. 
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Equations used for curve fitting and their derivation; 
 
Hill equation; 
 
A =agonist concentration, R = free receptor concentration 
A R = concentration of receptor and agonist complex 
RT = Total concentration of all receptors regardless of state 
n = number of agonists that need to bind to activate each receptor complex. 
KB = dissociation constant for AR 
A + nR ↔ A R 
From the law of mass action at equilibrium KB = An.R/ AR  (1) 
Assuming measured response, as ratio of maximal response is equal to 
fractional binding. 
Relative response =Y 
Y= AR/RT 
Y=AR/(R+AR) 
Substituting for AR from (1) AR= An.R / KB 
Y =   
  
 An.R / KB 
        R + An.R/ KB  
        
Eliminating R and multiplying by KB 
 
Y =           An         (2) 
           An +   KB 
 
As it is known that the muscarinic receptor binds to a single agonist n =1 was 
used for curve fitting. 
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Schild equation 
Consider agonist A competing with antagonist B for receptor binding site R 
with dissociation constants KA and KB respectively. 
The receptor can be in one of three states, either free R, Agonist bound AR or 
antagonist bound BR. The total available receptor concentration RT = R +AR 
+BR. 
Assuming fractional response Y is equal to fractional binding with the agonist 
A then 
Y =       AR/ R +AR +BR       (3) 
Assuming that A can only bind to R and not to BR and B can only bind to R 
and not AR then from the law of mass action,  then from (1) 
KA  = An.R/AR         (4) 
And 
KB  = Bn.R/BR         (5) 
Inverting (3) 
1/Y   =          R + AR + BR 
                   AR 
Substituting for AR and BR utilising (4) and (5) 
1/Y  =      R + An.R/ KA + Bn.R /KB     (6) 
       An.R / KA 
 
Dividing by R and inverting the equation 
 
Y   =   An / KA   
       1+ An / KA + Bn/KB 
 
Multiplying by KA  
 
Y  =             An      (7) 
      An + KA (1+ Bn/KB) 
    
 
 181
It can be seen from this equation that if there is no antagonist B then the 
equation is the same as the Hill equation 2. 
The complex KA (1+ Bn/KB) is the apparent dissociation constant derived from 
a curve fit in the presence of the antagonist which is a larger value than KA in 
the absence of the antagonist and when expressed as a ratio of KA it is known 
a the dose ratio (DR). A dose ratio of 2 is derived when 1+ Bn/KB =2 ie when 
Bn = KB.  
In a schild plot the log10 of the dose ratio- 1 is plotted against the log10 of the 
antagonist concentration. 
DR =1 + Bn/KB        (8) 
DR-1 = Bn/KB         (9) 
Taking the log10 of both sides 
log10 (DR-1) = n.log10B – log10KB      (10) 
– log10KB is also known as the pKB  then 
log10 (DR-1) = n.log10B + pKB      (11) 
In a Schild plot with log10 (DR-1) on the y axis and log10B on the x axis a linear 
graph is expected where the x intercept derives pKB the experimentally 
derived binding constant which is also known as the pA2 as it occurs when the 
dose ratio is 2 and log10 (DR-1) = 0. The slope of the plot is n is the hill 
number which is typically 1 for one to one binding but can be higher if more 
than one agonist needs to bind to the receptor to form an activated complex. It 
can be less than one if there is more than one receptor population to which 
the agonist may bind and elicit a response. The schild plot and the slope were 
set to one where there was significant deviation from unity. The shortened 
value of the Schild equation, which derives the pKB by applying, a slope of 1 
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to the point representing the lowest concentration of antagonist and 
extrapolating this line to the x axis. 
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Chapter 7 
 
References 
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